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Abstract 
 
 
High-throughput Next Generation RNA sequencing (RNA-Seq) technology is 
affluent with information about the transcriptome, which includes both protein-
coding and multiple non-coding regions. In a diseased state, complex 
interactions between these regions can go awry. Identification of such 
interactions is critical to translate the underlying biology of the transcriptome, 
especially for lethal diseases such as cancer. The field of bioinformatics is 
currently deficient in workflows that can analyze both coding and non-coding 
regions together efficiently, to identify disease-specific interactions.  
 
In this dissertation, I developed three coherent bioinformatics solutions that aim 
to address these shortcomings in RNA-Seq. First, a comprehensive workflow 
called MAPR-Seq was developed to analyze and report various features of 
protein-coding messenger RNAs. Second, a workflow for non-coding circular 
RNAs, called Circ-Seq, was developed to identify, quantify and annotate 
expressed circular RNAs. Third, an integration workflow called ReMIx was 
developed to identify microRNA response elements (MREs) and integrate them 
with the different types of RNAs (messenger RNAs, circular RNAs, and 
microRNAs).  
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Collectively, the three workflows were applied to the largest cohort of breast 
cancer samples (n=885) from The Cancer Genome Atlas (TCGA). Based on the 
results obtained from these workflows, I present several key findings that are 
pertinent to breast cancer. I show that circular RNAs may be a marker for tumor 
proliferation in estrogen response positive (ER+) breast cancer subtype. I also 
show how triple negative (TN) breast cancer subtype-specific MRE signatures of 
messenger RNA – microRNA interactions can be obtained using RNA-Seq data, 
which has not been explored to date and thus, is a novel undertaking. In the end, 
my results highlight candidate messenger RNAs, circular RNAs and microRNAs 
that are found to be associated with MAPK and PI3K/AKT signaling cascades in 
TN breast cancer subtype.    
 
In general, the developed bioinformatics solutions can also be applied to RNA-
Seq data of other cancer subtypes and diseases to identify unique messenger 
RNA – microRNA – circular RNA candidates that could be promising diagnostic 
targets towards improving treatment options for complex diseases. 
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Chapter 1: Introduction  
 
 
1.1 Evolutionary expansion of the genome 
Historically, scientists and researchers have been keen on studying genomic 
size, evolution and functional significance in numerous species [1-3]. During the 
era of the 1950s, it was assumed that genomic size correlates with organism 
complexity [4]. Scientists strongly believed that humans are one of the most 
complex species on earth and thus would have the largest genome with a 
maximum number of genes. However, this theory was proven wrong when it was 
discovered in 1971 that lower animals such as salamander have a genome 15 
times larger than that of humans [5]. This was a troubling paradox for many 
years. Later, experimental advances revealed that the genome is comprised of 
protein-coding and non-coding regions [6]. It was found that while a small subset 
is protein-coding, the non-coding content in the genomes of these different 
species varied by several folds [7, 8]. Since 2003, with the revolution of 
sequencing technologies and formation of the Encyclopedia of DNA Elements 
(ENCODE) consortium led by the US National Human Genome Research 
Institute (NHGRI), the mystery began to unfold by itself. It became surprisingly 
evident that non-coding regions of the genome also undergo transcription and, as 
shown in Figure 1, the number of transcribed non-coding regions increased for 
higher species [9, 10]. Thus it was clear, that the non-coding content has 
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undergone evolutionary expansion, suggesting their potential to correlate with 
organismal complexity.  
                     
Figure 1: Evolutionary expansion of non-coding regions in various organisms 
  
1.2 Current landscape of the human transcriptome 
As mentioned above, one of the many surprises that came from the ENCODE 
project was that over 70% of the non-coding regions in the human genome are 
transcribed and that only 2% of the genome encodes for proteins [10]. In 2012, 
the GENCODE project (Encyclopedia of genes and gene variants) emerged, 
leading to the categorization of transcribed, non-coding RNA molecules into 
several classes based on their characteristics and functional implications in the 
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genome [11]. It is worth a mention that even at present, the research community 
continues to discover new, unfound members of the non-coding RNA family as 
their presence continues to become evident using the latest and greatest 
sequencing technologies coupled with bioinformatics techniques.  
 
Non-coding RNAs have been broadly classified into categories such as long non-
coding RNAs (lncRNAs), small non-coding RNAs (sncRNAs), pseudogenes and 
an unclassified category of unprocessed transcripts (which consist of less 
understood genes that eventually get characterized based on on-going research 
and validation techniques) – for example, circular RNAs. The lncRNAs are 
defined as RNA molecules longer than 200 bases which exert pre- and post-
transcriptional regulatory effects on their messenger RNA (mRNA) counterparts 
[12]. The sncRNAs are typically 25 – 30 bases long which have a variety of 
functional and regulatory mechanisms and thus have been distinguished further 
into many more specific types such as transfer RNAs, ribosomal RNAs, small 
nucleolar RNAs, microRNAs, small interfering RNAs, etc. [13, 14]. Pseudogenes 
are non-functional relatives of mRNAs that have lost their protein-coding capacity 
due to various alterations [15]. Finally, circRNAs are non-canonical back-spliced 
by-products of transcription that form the most recent addition (discovered in 
2013 in humans) to the family of noncoding RNAs [16]. 
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In summary, according to the latest GENCODE version (v19) of human genome 
build hg19, the human transcriptome consists of 58,050 genes which comprise of 
35% mRNAs, 24% lncRNAs, 15% sncRNAs, 24%pseudogenes and 2% 
unclassified/unprocessed transcripts (which includes circRNAs). 
 
1.3 Types of RNA considered in this dissertation 
In this dissertation, I will focus on protein-coding mRNAs and two types of non-
coding RNAs, namely, microRNAs and circRNAs. This dissertation is an 
integrated study of these three RNA types. 
 
1.3.1 Messenger RNAs 
Messenger RNAs (mRNAs) are a well-studied class of RNA molecules that carry 
genetic codes from DNA in the nucleus to sites for protein synthesis in the 
cytoplasm. Structurally, mRNAs comprises of the following in the given order: 5’ 
cap, 5’ untranslated region (UTR), coding exons, 3’ untranslated region, poly-
adenylated (poly-A) tail. The poly-A tail protects the mRNA from degradation by 
exonucleases. However, the untranslated regions, especially the 3’UTR, can 
serve as hot spots for binding of specific non-coding RNAs called microRNAs 
(explained below) to mediate degradation of the expressed gene.  
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1.3.2 MicroRNAs 
MicroRNAs, a distinct category of sncRNAs, are highly conserved, single-
stranded RNA molecules of approximately 22 bases in length. Mature 
microRNAs are formed based on a unique transcription process. Export of 
microRNAs from the nucleus to the cytoplasm is performed by employing the 
Drosha, Exportin-5 and Dicer enzymes. Once mature, microRNAs accomplish 
their regulatory functions through the RNA-induced silencing complex (RISC) 
[17]. MicroRNAs activate and guide the RISC complex towards their target 
mRNAs to regulate gene expression. The RISC complex recognizes microRNA 
response elements (MRE) present on the 3’UTR of target mRNAs for 
complementary base-pairing with microRNAs. The degree and nature of the 
complementarity between the microRNA and its target gene determines the gene 
silencing mechanism, i.e., whether the gene undergoes mRNA degradation 
(imperfect pairing) or translation inhibition (perfect pairing). 
 
1.3.3 Circular RNAs 
Circular RNAs (circRNAs) are the most recent class of non-coding RNAs which 
are produced by back-splicing (3’ to 5’) of precursor mRNAs after transcription. 
Unlike linear RNAs that contain free 5’ and 3’ ends, circRNAs have these ends 
joined together to form a covalently closed loop. Because circRNAs do not have 
5’ or 3’ ends, they are resistant to exonuclease-mediated degradation and are 
thus expected to be more stable than most linear RNAs in cells. Additionally, 
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since circRNAs arise from otherwise protein-coding genes, these molecules can 
also contain MRE sites for microRNA binding. The genomic size of circRNAs can 
range from few to several kilo-bases and thus can contain a large number of 
MRE sites. For example, CiRS-7, discovered in 2013 by Memczak et al [16], is a 
classic example of a circRNA and is a back-spliced product of the CDR1 gene. 
CiRS-7 was found in human, mouse and nematode brain and consisted of 63 
conserved MRE sites for miR-7 binding. Lately, it has also been shown that a 
subset of circRNAs can be translated into functional proteins [18]. 
 
1.4 Cross-talk between different RNA types 
The expression of cancer-relevant genes such as tumor suppressors and 
oncogenes is critical in diseases, such as cancer. Complex interactions between 
mRNAs, circRNAs, and microRNAs can greatly influence the post-transcriptional 
activity of such genes in a normal versus cancerous environment within the cell. 
More precisely, mRNAs and circRNAs contain microRNA binding sites, called 
MRE sites from hereon, that are complimentary to microRNA seed regions. As 
shown in Figure 2, mRNAs and circRNAs use their MRE sites to interact with 
microRNAs. It is known that the interactions between MRE sites on mRNA 
targets and microRNA seed regions can lead to decreased gene expression or 
even gene silencing [19, 20]. However, in the presence of circRNAs that share 
the same MRE sites as mRNA targets, this now exposes microRNAs to non-
unidirectional interactions. Such mRNAs and circRNAs can act as competing 
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endogenous RNAs (ceRNAs) and sequester the same pool of microRNAs using 
their common MRE sites. As a result, not all microRNAs necessarily bind to the 
mRNA targets anymore, and thus the gene expression can remain intact.  
 
Figure 2: Endogenous competition between mRNAs and circRNAs for a 
common pool of microRNAs 
 
This form of RNA cross-talk is crucial to understand because the stability of 
mRNA targets, or lack of stability – depending on how the ceRNAs and 
microRNAs interact, can cause significant impact to gene expression in a 
cancerous versus normal environment.  
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1.5 Importance of studying RNA interactions in Breast 
Cancer 
Breast cancer is the second most common cancer in the United States. Being 
cancer that is formed in the cells of the breasts, this disease is more common in 
women. Breast cancer can be non-invasive, invasive or metastatic. Also, 
depending on the molecular diagnosis, breast cancer can be classified into 
subtypes based on the hormonal status of three key hormone receptors – 
estrogen receptor (ER), progesterone receptor (PR) and human epidermal 
growth factor receptor (HER2). There are three major molecular subtypes for 
breast cancer, listed in the order of tumor aggressiveness – ER positive (65 - 
80%), HER2 positive (20%) and Triple Negative (10 – 20%).  
 
As mentioned above, among the various molecular subtypes, Triple Negative 
(TN) cancer is highly heterogeneous and one of the most severe forms of breast 
cancer. A TN patient is found negative for all three hormone receptors and has a 
poor prognosis. At present, treatments such as chemotherapy, surgery and 
radiation therapy or their combination are provided to TN patients; unfortunately, 
their response to such treatment strategies is indigent, many times with the 
relapse of the tumor. Due to such treatment failures, there is an incisive need to 
identify alternative strategies to treat these patients in a more targeted and 
precise fashion.  
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On the bright side, we are now in the era of the revolutionary and groundbreaking 
technology of genome sequencing which is both low-cost and fast, and is 
famously called the Next Generation Sequencing (NGS) technology. NGS, which 
became available at the onset of the 21st century [21], has now become the 
standard in bioinformatics for analysis of the genome. Amongst the multitude of 
sequencing platforms offered by NGS, transcriptome profiling, or RNA-Seq, has 
been a significant breakthrough [22]. The wealth of information offered by RNA-
Seq is so vast that it not only helps uncover numerous features of the protein-
coding regions, such as gene expression, single nucleotide variants (SNVs) and 
gene fusions but also helps mine similar details on expressed but untranslated, 
non-coding regions of the transcriptome, such as lncRNAs, pseudogenes, and 
even circRNAs. 
 
1.6  Availability of high-throughput NGS datasets 
 
With the advent of NGS, it was clear that this technology could have an 
enormous impact on life sciences and would be an invaluable resource for the 
research community to analyze genomic profiles of heterogeneous diseases 
such as cancer. Thus the National Cancer Institute (NCI) and the National 
Human Genome Research Institute (NHGRI) collaborated in 2006 and built The 
Cancer Genome Atlas (TCGA) consortium (https://cancergenome.nih.gov/). 
TCGA is a unique repository of high throughput sequencing data from several 
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NGS application types, such as DNA-Seq, RNA-Seq, microRNA-Seq, methyl-
Seq, etc. made available for many different cancer types. Several TCGA cases 
also have matched tumor and normal-adjacent tissues from the same patient 
available for most of the NGS data types, making individualized comparative 
genomics possible.  
 
While many studies have used TCGA datasets to  derive meaningful inferences 
for different cancers [23-25] successfully, many of these studies have been 
focused on a specific NGS application type. Very few bioinformatics projects [26-
30] have utilized TCGA data from different NGS application types to perform 
integrated analyses for a specific type of cancer. 
 
As stated in the previous section of this chapter – on the cross-talk between 
different RNA types, complex interactions between ceRNAs and microRNAs can 
lead to instability of tumor suppressors, oncogenes, and other relevant target 
genes, paving the way for tumor growth and progression. Such crosstalk 
between ceRNAs, i.e., mRNAs and circRNAs with microRNAs, has not yet been 
studied in breast cancer and is investigated for the first time in this dissertation, 
using TCGA breast cancer RNA-Seq data. This will be a novel undertaking, and 
we believe that results from this dissertation will provide a significant contribution 
towards the current knowledge base of medical research in breast cancer. 
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1.7 Challenges and Motivation 
 
Although several bioinformatics packages have been developed to analyze RNA-
Seq data [31-36], these are stand-alone packages that function independently, 
analyze different aspects of the transcriptome and cannot be plugged together 
easily. Distinct differences in software prerequisites and methodology of these 
packages make analysis of multiple features a challenging feat. One of the 
roadblocks in RNA-Seq data analysis has been the lack of easy integration of 
such packages as well as the absence of all-inclusive packages or workflows that 
can stand as a unified solution for interpreting the transcriptome at a broader 
scale.  
 
Another significant gap found in bioinformatics research is that the depth of 
information offered by RNA-Seq technology is often not utilized to its full extent. 
RNA-Seq data can be mined for both protein-coding and non-coding regions 
using comprehensive and novel bioinformatics techniques; however, this 
incredible opportunity has often been overlooked. Integrative analyses including 
both protein-coding and multiple non-coding regions, such as mRNAs and both 
circRNAs and microRNAs respectively, are essential to enable precise and 
deeper understanding of the expression, interaction, and regulation of these 
regions in the transcriptome. 
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Thus, in light of the above bioinformatics challenges as well as the open 
possibilities to utilize RNA-Seq data to explore coding and non-coding RNA 
interactions in cancer patients with both tumor and normal-adjacent samples 
from same patient, and importantly, with a devoted motivation to strive towards 
improving diagnostic targets in breast cancer, I hereby present my dissertation 
with the following objectives:   
 
1. Development of comprehensive bioinformatics workflows: develop 
bioinformatics workflows for the identification, characterization, and 
quantification of 
a. MRNAs (protein-coding) 
b. CircRNAs (non-coding), and 
c. Integration of mRNAs and microRNAs 
 
2. Bioinformatics workflows application in TCGA breast cancer: 
Application of the developed bioinformatics workflows to high-throughput 
TCGA RNA-Seq breast cancer dataset to detect mRNAs and circRNAs 
 
3. MRE quantification and RNA integration analysis in breast cancer: 
Analysis of TCGA breast RNA-Seq results from the three workflows and 
TCGA breast microRNA data to  
a. quantify microRNA response element (MRE) sites 
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b. identify differentially expressed MRE sites between tumor and 
normal-adjacent, and 
c. use results from MRE analysis to identify competing endogenous 
RNA networks in breast tumor that involve mRNAs, circRNAs, and 
microRNAs 
 
1.8 Outline of the chapters 
 
The objectives of my dissertation are formulated to address the challenges as 
listed in the section above specifically. The outcomes of these objectives are 
described in the subsequent chapters of this dissertation. A brief outline of these 
chapters is provided below. 
 
Chapter 2 introduces the Mayo Analysis Pipeline for RNA-Seq called MAP-RSeq 
[37]. MAP-RSeq is a comprehensive bioinformatics workflow developed for the 
identification of mRNAs from RNA-Seq data and can also be used to obtain 
various genomic features of mRNAs, such as gene and exon expression 
quantification, single nucleotide variants and gene fusions, for human as well as 
any well-annotated genome. MAP-RSeq can be used on high-performance 
computing clusters and can also be run on a single node. The comprehensive 
reporting style, as well as extensive post-analysis quality checks of MAP-RSeq, 
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offers an end-to-end solution to researchers for their RNA-Seq bioinformatics 
needs. 
 
Chapter 3 describes the bioinformatics workflow developed for the identification 
and characterization of circRNAs, called Circ-Seq [38]. Circ-Seq is a 
comprehensive and configurable workflow with unique filters designed to report 
expressed circRNA candidates. Furthermore, this chapter explains the results 
obtained from the application of Circ-Seq to a) breast cancer cell lines and b) the 
biggest cohort of breast cancer samples from the TCGA consortium. Validation 
experiments using qRT-PCR and Sanger sequencing of a 7kb long circRNA 
identified in MCF7 breast cancer cell line by Circ-Seq is also a significant part of 
the results in this chapter.  
 
Chapter 4 describes a novel bioinformatics approach called ReMIx that utilizes 
TCGA RNA-Seq data to integrate mRNAs and microRNAs by identifying and 
quantifying microRNA binding or MRE sites in tumor and normal-adjacent 
samples of the Triple Negative breast cancer subtype. Differentially expressed 
MREs are selected, and genes and microRNA candidates associated with these 
MREs are analyzed in further detail. Significant canonical pathways are 
identified, and the MRE-associated genes and microRNAs, as well as circRNAs 
that belong to the genes in these pathways, are studied to identify complex 
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interactions between mRNAs, circRNAs, and microRNAs in Triple Negative 
breast cancer.  
 
Chapter 5 is a conclusion of this dissertation. This chapter offers a quick recap of 
the bioinformatics challenges faced and the three specific objectives pursued in 
this dissertation. The results accomplished from individual objectives are 
outlined. Further, chapter 5 offers future insights into potential directions in which 
work from this dissertation can be carried forward.  
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Chapter 2: MAP-RSeq – Mayo Analysis Pipeline 
for RNA Sequencing 
 
 
2.1 Background 
 
Next-generation sequencing (NGS) technology breakthroughs have allowed us to 
define the transcriptome landscape for cancers and other diseases [39]. RNA-
Sequencing (RNA-Seq) is information-rich; it enables researchers to investigate 
a variety of genomic features, such as gene expression, characterization of novel 
transcripts, alternative splice sites, single nucleotide variants (SNVs), fusion 
transcripts, long non-coding RNAs, small insertions, and small deletions. Multiple 
alignment software packages are available for read alignment, quality control 
methods, gene expression and transcript quantification methods for RNA-Seq 
[40-43]. However, the majority of the RNA-Seq bioinformatics methods are 
focused only on the analysis of a few genomic features for downstream analysis 
[44-47]. At present, there is no comprehensive RNA-Seq workflow that can 
simply be installed and used for multiple genomic feature analysis. At the Mayo 
Clinic, we have developed MAP-RSeq - a comprehensive computational 
workflow, to align, assess and report multiple genomic features from paired-end 
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RNA-Seq data efficiently with quick turnaround time. We have tested a variety of 
tools and methods to estimate genomic features from RNA-Seq data accurately. 
Best performing publically available bioinformatics tools along with parameter 
optimization were included in our workflow. As needed we have integrated in-
house methods or tools to fill in the gaps. We have thoroughly investigated and 
compared the available tools and have optimized parameters to make the 
workflow run seamlessly for both the virtual machine and cluster environments. 
Our software has been tested with paired-end sequencing reads from all Illumina 
platforms. Thus far, we have processed over 5,000 Mayo Clinic samples using 
the MAP-RSeq workflow. The MAP-RSeq research reports for RNA-Seq data 
have enabled Mayo Clinic researchers and clinicians to exchange datasets and 
findings. Standardizing the workflow has allowed us to build a system that 
enables us to investigate across multiple studies within the Mayo Clinic. MAP-
RSeq is a production application that allows researchers with minimal expertise 
in LINUX or Windows to install, analyze and interpret RNA-Seq data. 
 
2.2 Availability and requirements 
 
Project name: MAP-RSeq 
Project home page: http://bioinformaticstools.mayo.edu/research/maprseq/ 
Operating system(s): Linux or VM 
Programming language: PERL, Python, JAVA, R, and BASH 
Other requirements: none 
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License: Open Source 
Any restrictions to use by non-academics: none 
 
2.3 Implementation 
 
MAP-RSeq uses a variety of freely available bioinformatics tools along with in-
house developed methods using Perl, Python, R, and Java. MAP-RSeq is 
available in two versions. The first version is single threaded and runs on a virtual 
machine (VM). The VM version is straightforward to install. The second version is 
multi-threaded and is designed to run on a cluster environment. 
 
2.3.1 Virtual machine 
 
Virtual machine version of MAP-RSeq is available for download at the provided 
URL [48]. This includes a sample dataset, references (limited to chromosome 
22), and the complete MAP-RSeq workflow pre-installed. Virtual Box software 
(free for Windows, Mac, and Linux at [49]) needs to be installed on the host 
system. The system also needs to meet the following requirements: at least 4GB 
of physical memory, and at least 10GB of available disk. Although our sample 
data is only from Human Chromosome 22, this virtual machine can be extended 
to the entire human reference genome or to other species. However, this 
requires allocating more memory (~16GB) than may be available on a typical 
desktop system and build the index references files for the species of interest. 
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Tables 1 and 2 shows the install and runtime metrics of MAP-RSeq in virtual 
machine and Linux environments respectively. For Table 2, we downloaded the 
breast cancer cell line data from CGHub [50] and randomly chose 4 million reads 
to run through the QuickStart VM. It took 6 hours for the MAP-RSeq workflow to 
complete. It did not exceed the 4GB memory limit but did rely heavily on the 
swap space provided; making it run slower than if it would have had more 
physical memory available. Job profiling indicates that the system could have 
used 11GB of memory for such a sample. 
 
QuickStart VM File size Timeline 
Download 2.2GB ~ 20 minutes to download on 
consumer grade internet 
Unpacked size 8GB - 
Time to import into VM - ~ 10 minutes 
VM boot - 3 minutes 
Runtime with sample data 
(chr22 only) 
- ~ 30 minutes 
 
Table 1: MAP-RSeq installation and runtime for QuickStart virtual machine 
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Linux File size Timeline 
Download 930 MB ~10 minutes to download on consumer 
grade internet 
Install time - ~6 hours (mostly downloading and 
indexing references) 
Unpacked size 9GB - 
Runtime - Depends on the sample data used 
 
Table 2: MAP-RSeq installation and runtime in a Linux environment 
 
 
2.3.2 Sun grid engine 
 
MAP-RSeq requires four processing cores with a total of 16GB RAM to get 
optimal performance. It also requires 8GB of storage space for tools and 
reference file installation. For MAP-RSeq execution the following packages such 
as JAVA version 1.6.0_17 or higher, Perl version 5.10.0 or higher, Python 
version 2.7 or higher, Python-dev, Cython, Numpy and Scipy, gcc and g++ , Zlib, 
Zlib-devel, ncurses, ncurses-devel, R, libgd2-xpm, and mailx need to be 
preinstalled and referenced in the environment path. It does also require having 
additional storage space for analyzing input data and writing output files. MAP-
RSeq uses bioinformatics tools such as BEDTools [34], UCSC Blat [51], Bowtie 
[52], Circos [53], FastQC [54], GATK [33], HTSeq [55], Picard Tools [56], 
RSeqQC [57], Samtools [58], and TopHat [59]. Our user manual and README 
files provide detailed information of the dependencies, bioinformatics tools and 
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parameters for MAP-RSeq. The application requires configuration, such as run, 
tool, and sample information files, as described in the user manual. 
 
Table 3 shows the processing time of the workflow across different sequencing 
read depths. Time was recorded from a server with eight quad-core Intel Xeon 
2.67 GHz processors and 530 GB of shared memory using Centos 6. For a 
sample with 1 million reads, MAP-RSeq completes in less than 2 hours. For 
samples with 150 million to 300 million reads, MAP-RSeq completes in 12-48 
hours depending on the hardware used. 
 
MAP-RSeq processing time Read Counts 
118 minutes 1,000,000 
82 minutes 500,000 
71 minutes 200,000 
 
Table 3: Wall clock times to run MAP-RSeq at different read counts 
 
2.4 Results 
 
NGS technology has been outpacing bioinformatics. MAP-RSeq is a 
comprehensive simple-to-use solution for analysis of RNA-Sequencing data. We 
have used both simulated and real datasets to optimize parameters of the tools 
included in the MAP-RSeq workflow. The high-level design of MAP-RSeq is 
shown in Figure 3. MAP-RSeq consists of the six major modules such as 
alignment of reads, quality assessment of sequence reads, gene expression and 
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exon expression counts, expressed SNVs from RNA-Seq, fusion transcript 
detection, summarization of data and final report. 
 
Reads are aligned by TopHat 2.0.6 [59] against the human reference genome 
build (default = hg19) using the bowtie1 aligner option. Bowtie is a fast memory 
efficient, short sequence aligner [52]. The remaining unaligned reads from Bowtie 
are used by TopHat to find splice junctions and fusions. At the end of the 
alignment step, MAP-RSeq generates binary alignment (BAM) and junction bed 
files for further processing. The workflow uses the RSeQC software [57] to 
estimate the distance between paired-end reads, evaluate sequencing depth for 
alternate splicing events, determine the rate of duplicate reads, and calculate 
coverage of reads across genes as shown in the example report file (Figure 4). 
The summary statistics and plots generated by MAP-RSeq workflow are used for 
further quality assessments. The example MAP-RSeq result set (files and 
summary report) from a RNA-Sequencing run can be downloaded from the MAP-
RSeq homepage [48]. 
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Figure 3: Flowchart of the MAP-RSeq workflow. High-level representation of the 
MAP-RSeq workflow for processing RNA-Seq data. 
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Figure 4: Screenshot output report (html) of MAP-RSeq. An example screenshot 
report of the MAP-RSeq output file. 
 
Several research and clinical projects [60-62] at Mayo Clinic have applied MAP-
RSeq workflow for obtaining gene expression, single nucleotide variants and 
fusion transcripts for a variety of cancer and disease-related studies. Currently, 
there are multiple ongoing projects or clinical trial studies for which we generate 
both RNA-Sequencing and exome sequencing datasets at the Mayo Clinic 
Sequencing Core. We have developed our RNA-Seq and DNA-Seq workflows 
such that sequencing data can be directly supplied to the pipelines with less 
manual intervention. Analysis of the next generation sequencing datasets along 
with phenotype data enables a further understanding of the genomic landscape 
to better diagnose and treat patients. 
 
  25 
2.4.1 Gene expression and exon expression read counts 
 
A Gene expression count is defined as the sum of reads in exons for the gene 
whereas an exon expression count is defined as the sum of reads in a particular 
exon of a gene. Gene expression counts in MAP-RSeq pipeline can be obtained 
using HTSeq [55] software (default) or featureCounts [32] software. The gene 
annotation files were obtained from the Cufflinks website [63]. Exon expression 
counts are obtained using the intersectBed function from the BEDTools Suite 
[34]. 
 
MAP-RSeq gene expression counts module was validated using a synthetic 
dataset for which RNA-Seq reads were simulated using the BEERS software - a 
computational method that generates paired-end RNA-sequencing reads for 
Illumina platform [64]. The parameters used for BEERS to generate simulated 
data are: total reads = 2 million reads, hg19 annotation from RefSeq, read 
length = 50 bases, base error = 0.005 and substitution rate = 0.0001. Simulated 
reads were aligned and mapped using the MAP-RSeq workflow. The mapped 
reads were then input into HTSeq for gene expression counts. Genes with fewer 
than 30 reads were excluded from the analysis. A correlation of r = 0.87 was 
observed between the Reads Per Kilobase per Million (RPKM) simulated gene 
counts and the counts reported by MAP-RSeq, as shown in Figure 5.  
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Figure 5: Correlation of gene counts reported by MAP-RSeq in comparison to 
counts simulated by BEERS. MAP-RSeq uses the HTSeq software to classify 
reads to genomic features. The intersection nonempty mode of HTSeq was 
applied, and the query-name sorted alignment (BAM) file along with the 
reference GTF file obtained from BEERS were provided as input files to HTSeq 
for accurate assignment of paired-end reads to genomic features. Comparison of 
the gene counts (RPKM) obtained from MAP-RSeq with counts for respective 
genes simulated by BEERS yielded a Pearson correlation of 0.87. The genomic 
regions where gene expression reported by HTSeq did not completely correlate 
with simulated expression are due to ambiguous reads or due to the fact that 
either mate of the paired-end read mapped to a different genomic feature, thus 
categorizing the read as ambiguous by HTSeq. 
 
 
For simulated data (50 bases), Table 4 summarizes various statistics reported by 
the MAP-RSeq workflow regarding the alignment of reads to transcriptome and 
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junctions, gene and exon abundance as well as number of SNVs identified and 
annotated using GATK.  
 
MAP-RSeq features Statistics 
Total number of single reads 4,000,000 
Reads used for alignment 3,999,995 
Total number of reads mapped 3,851,539 (96.3%) 
Reads mapped to transcriptome 3,401,468 (85.0%) 
Reads mapped to junctions 450,071 (11.3%) 
Reads contributing to gene abundance 1,395,844 
Reads contributing to exon abundance 11,266,392 
Number of SNVs identified 6,222 
 
Table 4: Alignment statistics from MAP-RSeq using a simulated dataset from 
BEERS 
 
 
An example of MAP-RSeq gene counts table; exon counts table, and normalized 
counts (RPKM) along with annotations for each run are shown in Figure 6. 
  28 
 
Figure 6: Screenshots of gene and exon expression reports by MAP-RSeq. An 
example of the gene and exon expression counts from the output reports of 
MAP-RSeq. 
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2.4.2 Differential expression 
 
Each sample is associated with a phenotype, such as a tumor, normal, treated, 
control, etc and that meta-data needs to be obtained to form groups for 
differential expression analysis. To remove any outlier samples, it is required to 
perform detailed quality control checks prior to gene expression analysis. There 
are a variety of software packages that are used for differential expression 
analysis using RNA-Seq gene expression data [42, 65-67]. Several studies have 
been published comparing the differential expression methods and concluded 
that there are substantial differences regarding sensitivity and specificity among 
the methods [68-70]. We have chosen edgeR software [42] from R statistical 
package for gene expression analysis. In our source code for MAP-RSeq 
pipeline, we have Perl, R scripts and instructions that can be used post MAP-
RSeq run for differential expression analysis. 
 
2.4.3 Expressed SNVs (eSNVs) from RNA-Seq 
 
After filtering out multiple mapped and fusion reads, the MAP-RSeq calls SNVs 
using UnifiedGenotyper v.1.6.7 and VariantRecalibrator from Genome Analysis 
ToolKit (GATK) with the alignment files generated by Tophat. The 
UnifiedGenotyper from GATK is a single nucleotide variant (SNV) and indel caller 
developed by the BROAD institute [33]. SNVs are further annotated by the 
variant quality score recalibration (VQSR) method. The annotated SNVs are 
further filtered based on read quality (QD), coverage (DP), strand bias (FS), and 
  30 
positional bias (ReadPosRankSum) to identify true variants. A 1000 genome 
sample (NA07347) with both exome and RNA-Seq data was used to validate the 
SNV calling module of MAP-RSeq workflow. A concordance rate of 95.6% was 
observed between the MAP-RSeq SNV calls, and the exome sequencing variant 
calls for NA07347. Figure 7 shows a screenshot of the MAP-RSeq variant calling 
file. Confident variant calls from MAP-RSeq workflow at high and low read depths 
of sequencing are shown in Figure 8A and 8B respectively. 
 
 
Figure 7: Screenshot of a MAP-RSeq VCF file after VQSR annotation. An 
example of SNV data representation from MAP-RSeq runs. 
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Figure 8: Examples of SNVs called in RNA and DNA data for NA07347. An IGV 
screenshot representation of SNV regions for the 1000 genome sample 
NA07347 A) at high read depths called in RNA when compared to exome/DNA 
data and B) at low read depth called in RNA when compared to exome/DNA 
data. 
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2.4.4 Fusion transcript detection 
 
The TopHat-Fusion algorithm identifies fusion transcripts accurately [31]. MAP-
RSeq uses the TopHat-Fusion algorithm and provides a list of expressed fusion 
transcripts. In addition to the output from TopHat-Fusion, we have implemented 
modules to visualize fusion transcripts using circos plots [53]. Fusion transcript 
candidates are reported and summarized by MAP-RSeq. As shown in Figure 9, 
intra and inter fusion transcripts along with annotations are provided for each 
sample by the workflow. A circos plot is generated to visualize fusion transcripts 
across an entire RNA-Seq run. MAP-RSeq also generates 5′–3′ fusion spanning 
sequence for PCR validation of fusion transcripts identified. These primer 
sequences can be selected by researchers to validate the fusion transcripts. 
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Figure 9: Fusion transcripts reported by MAP-RSeq. An example of the fusion 
transcripts output file from MAP-RSeq workflow. 
 
 
  34 
2.4.5 Summarization of data and final report 
 
The workflow generates two main reports for end users: 1) summary report for all 
samples in a run with links to detailed reports and six QC visualizations per 
sample 2) final data report folder consisted of exon, gene, fusion and expressed 
SNV files with annotations for further statistical and bioinformatics analysis. 
 
A screenshot of an example report from MAP-RSeq is shown in Figure 4. 
Detailed descriptions of the samples processed by MAP-RSeq along with the 
study design and experiment details are reported by the workflow. Results are 
summarized for each sample in the report. Detailed quality control information, 
links to gene expression counts, exon counts, variant files, fusion transcript 
information and various visualization plots are also reported. 
 
2.5 Conclusions 
 
MAP-RSeq is a comprehensive simple-to-use application. MAP-RSeq reports 
alignment statistics, in-depth quality control statistics, gene counts, exon counts, 
fusion transcripts, and SNVs per sample. The output from the workflow can be 
plugged into other software or packages for subsequent downstream 
bioinformatics analysis. Several research and clinical projects at the Mayo Clinic 
have used the gene expression, SNVs and fusion transcripts report from the 
MAP-RSeq workflow for a wide range of cancers and other disease-related 
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studies. In future, we plan to extend our workflow such that alternate splicing 
transcripts and non-coding RNAs can also be obtained. 
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Chapter 3: CircRNAs and their associations with 
breast cancer subtypes 
 
 
3.1 Introduction 
 
Circular RNAs (circRNAs) are recently discovered members of noncoding RNAs. 
They range in length from a few hundred to thousands of nucleotides [71]. In 
contrast to linear RNA transcripts, which are normally spliced tail-to-head, 
circRNAs are formed by the covalent bonding of their 3′ and 5′ (head-to-tail) ends 
[72]. The lack of open sites at the 5′ and 3′ ends exempts circRNAs from 
exonuclease degradation [73], making them stable in cells [74]. When circRNAs 
were initially identified in plants, they were considered pathogenic because of 
their structural similarity to viruses [75, 76]. Meanwhile, circRNAs observed in 
mammalian cells around the same time were thought to result from splicing 
errors [77-79]. However, more recent studies of circRNAs in Drosophila, mouse, 
and other eukaryotes suggest that these RNA molecules are evolutionarily 
conserved and thus are not simple artifacts of faulty splicing [80, 81]. In addition, 
advances in sequencing technology and bioinformatics analyses have renewed 
interest in these forms of RNA transcripts [16, 72, 82]. 
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After discovering that circRNAs are highly abundant in not only C. elegans and 
zebrafish, but also mouse and human, researchers have begun to uncover many 
intriguing facets about these diverse RNAs [73]. Many studies have confirmed 
that circRNAs possess significant pre- and post-transcriptional regulatory 
functions in mammalian cells [71, 82, 83] and changes in the abundance of 
circRNAs can adversely affect gene expression [84, 85]. Recent studies indicate 
that some of the most common functions of circRNAs include their active 
participation in pre-mRNA splicing [80] as well as promoting transcription of their 
parent mRNAs [86]. Apart from the above, circRNAs can sometimes serve as 
microRNA sponges, such as the human circRNA CDR1as, which was shown to 
contain over 70 binding sites for miR-7 [16, 87]. 
 
Stable, cell-free circRNAs have been found in saliva [88] and exosomes [89], 
making them promising candidates for diagnosis and therapeutics. In particular, 
discovering disease-specific circRNAs could help identify diagnostic targets in 
heterogeneous diseases such as cancer. Memczak et al. and Salzman et al. 
have developed bioinformatics approaches to detect circRNAs using high-
throughput transcriptome sequencing, and to date, several hundred human 
circRNAs have been identified and cataloged [16, 72, 90]. However, the 
significance of these RNAs in health and disease is still poorly understood. 
Recently, Bachmayr-Heyda et al. reported that colorectal tumor samples have a 
lower number of circRNAs compared to matched normal colon mucosa [91]. It is 
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known that circRNAs are also associated with single nucleotide polymorphisms 
linked to a wide range of diseases, including various types of cancer, Parkinson’s 
disease, Alzheimer’s disease, multiple sclerosis, and schizophrenia [92]. 
 
Here, we have enhanced existing methodologies of circRNA detection [16] and 
developed a parallelized and configurable workflow, Circ-Seq, that annotates and 
reports expressed and exclusive circRNAs as final candidates from the analysis. 
We applied Circ-Seq to one of the largest transcriptome sequencing data 
available for breast cancer samples, provided by The Cancer Genome Atlas 
(TCGA) consortium. We identified unique and novel circRNAs present in breast 
tumor samples and normal-adjacent breast tissue. We identified circRNAs 
specific to breast tumor samples and cataloged circRNAs unique to each of the 
three breast cancer subtypes: triple negative (TN), estrogen receptor positive 
(ER+), and ErbB2 overexpressed–HER2 positive (HER2+). Notably, a lower 
number of circRNAs were observed in breast tumors compared to both normal-
adjacent breast tissues from TCGA as well as normal mammary tissue samples 
from GTEx. Finally, using a panel of 11 cell proliferation gene markers (ROR-P 
score), we show that the number of circRNAs detected in the ER+ tumor is 
associated with gene proliferation markers [93]. We also demonstrate that 
Luminal B tumors have a distinct trend compared to Luminal A tumors based on 
their circRNA numbers. On the basis of its ability to detect circRNAs in breast 
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cancer samples, we believe that Circ-Seq will be a valuable tool for researchers 
to identify circRNAs for diagnosis and treatment of complex diseases. 
3.2 Results 
 
 
3.2.1 Circ-Seq: an automated workflow for circRNA identification 
 
Using existing bioinformatics approaches for circRNA identification by Memczak 
et al. [16], we developed an integrated analytical workflow called Circ-Seq, for 
identifying and characterizing circRNAs using high-throughput transcriptome 
sequencing data. Briefly, it improves the existing methodology by applying filters 
namely, expression, genomic size, and validation filters, to report a more 
confident and final catalog of expressed candidate circRNAs. The expression 
filter retains circRNAs based on the desired number of junction-spanning reads, 
which is configurable based on sequencing throughput of the sample being 
analyzed. Next, the genomic size filter is applied to discard any circRNA 
candidate with tail-to-head genomic distance less than six bases. Finally, the 
validation filter uses BLAT [51] to query circRNAs to ensure they do not 
represent repetitive regions of the genome. Towards the end of the workflow, 
circRNA fused junctions of the final candidates are annotated with valuable 
genomic information. Annotation of whether the circRNA is a spliced product of a 
single gene (‘intra-gene’) or formed across 2 or more genes (‘inter-gene’), and 
exon location of its 3′ and 5′ ends (‘exon-exon boundary’ or ‘within_exon’) are 
provided for users discretion to prioritize circRNA candidates in the final report. 
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The workflow is fully automated and designed to run in a multi-threaded cluster 
environment and can also be used to analyze single-end or paired-end 
transcriptome samples. Circ-Seq workflow can be downloaded from 
(http://bioinformaticstools.mayo.edu/research/circ-seq/). 
 
3.2.2 Identification of circRNAs in breast cancer cell lines 
 
To demonstrate the utility of Circ-Seq, we first tested the workflow on the 
transcriptomes of eight cell lines – seven from breast tumors (BT20, BT474, 
MCF7, MDAMB231, MDAMB468, T47D, and ZR751) and one from non-tumor 
breast cell line (MCF10A) [94], and validated one of the largest circRNA 
candidates reported by the workflow. 
 
CircRNAs were expressed in both the tumor and normal breast cell lines. As 
shown in Table 5, we identified an average of 10 circRNAs in the triple negative 
(TN) cancer cell lines, 22 in the estrogen receptor positive (ER+) cancer cell 
lines, and 9 in the non-tumor MCF10A cell line. On average, circRNAs detected 
in the cancer cell lines had 12 junction supporting reads in both TN and ER+ 
subtypes. Assuming that the exon-intron structures of circRNAs remain intact 
[86], we observed variable genomic sizes for circRNAs in the tumor and non-
tumor cell lines. While the smallest circRNA was of size 51 bases in the tumor 
(ZR751 and BT474) and 70 bases in the non-tumor MCF10A, large circRNAs 
with genomic sizes exceeding 5kb were found in MCF7, BT474, ZR751 and 
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MDAMB231 tumor lines. After annotating the head-to-tail fused junctions of these 
circRNAs with gene models, we found that 31% of circRNAs are spliced products 
of a single gene (intra-gene) and 12% are inter-gene circRNAs. Additionally, 25% 
of the circRNAs have their head-to-tail fused junctions along legitimate exon-
exon boundaries whereas 18% were found with circRNA junctions inside exons 
and not on the exon boundaries.  
 
Cell line Tissue Breast 
Cancer 
Subtype 
Total number 
of circRNAs 
identified 
Final number of 
circRNAs (after 
three filters) 
Average number of 
circRNA junction 
supporting reads 
MDAMB231 Tumor TN 1,111 10 11.2 
MDAMB468 Tumor TN 2,540 15 9.8 
BT20 Tumor TN 1,592 6 15 
BT474 Tumor ER+ 4,662 43 14.5 
ZR751 Tumor ER+ 3,148 31 11.1 
T47D Tumor ER+ 1,306 5 13.2 
MCF7 Tumor ER+ 1,838 9 10 
MCF10A Non-
Tumor 
– 1,363 9 10.4 
 
Table 5: Number of circRNAs identified in breast cell lines using the Circ-Seq 
workflow 
 
3.2.3 Validation of circRNA in MCF7 breast cancer cells 
 
To establish the reliability of circRNA candidates reported by Circ-Seq, we 
validated one of the largest circRNAs identified in MCF7, the most widely 
accessible tumor breast cell line that was available in-house. Circ-Seq results for 
MCF7 indicated that 2 out of 9 circRNAs were found to span legitimate exon-
exon boundaries, of which one had a genomic size of 64 bases and the other 7 
  42 
kb. Since some circRNAs were previously reported to act as microRNA sponges 
and thus had to be long enough to harbor multiple microRNA binding sites [87], 
we decided to select the largest out of the two circRNAs in MCF7 for validation. 
This circRNA was found at chr14:102,466,325–102,500,789 and had 12 
supporting junction-spanning reads. The validation consisted of using two 
independent sets of qRT-PCR experiments. To validate the existence of 
circRNAs, two different primers were prepared – convergent and divergent [16]. 
Convergent primers are traditional primers that confirm the existence of linear or 
tail-to-head (5′ to 3′) RNA transcripts, however divergent primers are designed in 
a circular or head-to-tail fashion (3′ to 5′) to enable binding to circRNA fragments 
for validation. As shown in Figure 10A, the divergent primer amplified circRNA 
from MCF7 total RNA but not from genomic DNA (gDNA) whereas GAPDH, 
which was used as a control, had no results from divergent primers but confirmed 
its linear RNA using convergent primers. Additionally, Sanger sequencing of the 
qRT-PCR product validated the head-to-tail splicing. In Figure 10B, the 
underlined genomic sequence CAATAGGGCAACCTT represents the circRNA 
spliced junction with the 3′ tail fusing to 5′ head at the highlighted ‘G’ nucleotide. 
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Figure 10: Validation of a circRNA at locus chr14:102,466,325–102,500,789. (A) 
circRNA was amplified by divergent primers using total RNA but not genomic 
DNA (gDNA). GAPDH was used as a control. (B) Head-to-tail splicing was 
confirmed by Sanger Sequencing. 
 
 
3.2.4 Presence of circRNAs in TCGA breast cancer 
transcriptomes 
 
We applied Circ-Seq workflow to 885 whole-transcriptome sequences from 
breast tumor and normal-adjacent samples provided by the TCGA consortium. 
Our goal was to use this unique repository to identify circRNAs that differ 
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between normal-adjacent and tumor tissue. CircRNA results from the workflow 
for 885 RNA-Seq breast TCGA samples are available for download at 
https://noncodingrnaexplorer.wordpress.com. 
 
3.2.4.1 Breast cancer subtype analysis 
 
3.2.4.1.1 circRNAs in tumors and normal-adjacent tissue 
Using the Circ-Seq workflow, we processed 128 tumor and 13 normal-adjacent 
TN samples, 503 tumor and 56 normal-adjacent ER+ samples, and 162 tumor 
and 20 normal-adjacent HER2+ samples. As shown in Table 6, we observed a 
total number of 4,542 and 342 circRNAs in tumor and normal-adjacent samples 
respectively for the TN subtype. Next, we found the number of unique circRNAs 
that represented exclusive genomic coordinates in tumor and normal-adjacent 
samples. Note that a unique circRNA is counted once although it may occur in 2 
or more samples with the same genomic coordinate. We observed 1,395 unique 
circRNAs in TN tumor samples and 208 circRNAs in normal-adjacent tissue 
samples. Similarly, we identified 14,113 (total) and 3,012 (unique) circRNAs in 
ER+ tumor samples and 2,317 (total) and 1,409 (unique) circRNAs in normal-
adjacent tissue samples. Finally, 6,340 (total) and 2,660 (unique) circRNAs were 
identified in HER2+ tumors and 532 (total) and 284 (unique) in normal-adjacent 
tissue samples. A summary of the unique circRNAs for the three breast cancer 
subtypes is shown in Table 6. 
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 Triple Negative 
(TN) 
Estrogen 
Receptor (ER+) 
ERBB2 
overexpressed 
(HER2+) 
Categories Tumor Adjacent Tumor Adjacent Tumor Adjacent 
Total number of samples 128 13 503 56 162 20 
Total number of circRNAs 4,542 342 14,113 2,317 6,340 532 
Total number of unique circRNAs 1,395 208 3,012 1,409 2,660 284 
Ratio of total circRNAs to samples 35 26 28 41 39 27 
Ratio of unique circRNAs to samples 12 16 7 25 17 14 
Number of unique circRNAs seen in 
10% or more samples 
729 162 1,086 455 896 193 
Number of tumor-specific circRNAs 256 – 288 – 411 – 
 
Table 6: Summary of breast tumors, adjacent tissues, and tumor-specific 
circRNAs in sequence data made available by the cancer genome atlas 
 
We further investigated the unique circRNAs between tumor and normal-adjacent 
to find circRNAs distinct to the tumor. We observed that normal circRNAs 
spanned larger genomic regions (from 3′ head to 5′ tail). Interestingly, within the 
same genomic region of the normal circRNAs, we found one or more smaller 
circRNAs that belonged to the tumor samples. Assuming that circRNAs coming 
from the same region have similar functional implications during transcriptional 
regulation, we considered such circRNAs as common candidates between tumor 
and normal-adjacent tissues. Therefore, if a circRNA was identified in tumor and 
not in the normal-adjacent tissue, we termed such candidates as tumor-specific 
circRNAs and found 256, 288 and 411 tumor-specific circRNAs in TN, ER+ and 
HER2+ breast cancer subtypes respectively. 
 
Because the number of normal-adjacent samples was much smaller than the 
number of breast tumor samples (most tumor samples did not have a paired 
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normal-adjacent tissue sample), we also calculated the ratio of unique circRNAs 
to the number of samples. Interestingly, after normalization, we see that 
circRNAs have a higher count in normal-adjacent samples, as shown in Table 6. 
We tested the significance of this observation using ANOVA and found that 
normal-adjacent samples of ER+ subtype had a p-value < 8.96e–06 compared to 
the tumor. However, for TN and HER2+ subtypes the probability measure was 
insignificant (p-value > 0.05), and combining all subtypes also did not show a 
significant increase in a number of normal-adjacent tissue circRNAs (p-value 
0.11). 
 
3.2.4.1.2 Tumor-specific circRNAs in breast cancer cell lines also 
present in breast cancer tissues 
circRNAs from the TN and ER+ cancer cell lines were compared to those from 
the non-tumor MCF10A breast cell line (see Table 5 for subtype classification of 
cell lines; no HER2+ cell lines were available). This comparison yielded 10 TN-
specific and 53 ER+ –specific circRNAs (Figure 11A). We checked for common 
tumor-specific circRNAs between breast cancer cell lines and breast cancer 
TCGA samples. We also compared these circRNAs to the 256 circRNAs 
identified earlier in TCGA TN breast cancer samples and the 288 circRNAs 
obtained from TCGA ER+ breast cancer samples. As shown in Figure 11B, we 
found that three circRNAs were shared between TN breast cancer cell lines and 
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TCGA TN breast cancer samples, and 15 circRNAs were shared between ER+ 
breast cancer cell lines and TCGA ER+ breast cancer samples. 
 
 
Figure 11: TCGA tumor-specific circRNAs also found in breast cell lines. (A) 
overlap of circRNAs between different subtypes for breast cell lines, (B) overlap 
of TN and ER+ tumor-specific circRNAs between TCGA and cell lines. 
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3.2.4.1.3 Tumor-specific circRNAs are associated with cancer-related 
canonical pathways 
The TN, ER+, and HER2+ breast cancer subtypes have unique prognostic and 
therapeutic characteristics. Although the gene expression profiles of these 
subtypes are markedly different [95, 96], a shared population of genes behaves 
similarly across them. We observed a comparable trend for circRNAs. We found 
that 42 tumor-specific circRNAs were common across TN, ER+, and HER2+ 
subtypes. At the same time, we also observed 142 TN, 164 ER+ and 245 HER2+ 
tumor-specific circRNAs that are exclusive to each subtype. 
Because circRNAs have post-transcriptional regulatory functions and tend to 
influence overlapping or neighboring genes [16, 77], we annotated the tumor-
specific circRNAs with protein-coding genes using the Ensembl reference system 
(version GRCh37.75). Pathway analysis demonstrated that most tumor-specific 
circRNAs were associated with cancer-related canonical pathways. The 42 
circRNAs common to all three breast cancer subtypes were annotated with 45 
genes, of which 33 genes (p-value = 8.43E-05–4.09E-03) were associated with 
cancer-related pathways. As shown in Figure 12, these circRNAs are likely 
involved in various hormone signaling, immune cell communication, and OX40 
signaling pathways. The circRNAs (n = 142) unique to TN tumor samples were 
linked to a total of 370 genes of which 220 genes (p-value = 7.79E-06–1.26E-02) 
were associated with cancer pathways such as tight junction, antigen 
presentation, and mTOR signaling pathways. Likewise, HER2+-specific circRNAs 
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(n = 245), annotated with over 1,500 protein-coding genes, had 855 cancer-
related genes (p-value = 1.65E-14–2.24E-03) involved in Wnt signaling, Cdc42, 
and ILK signaling pathways. The ER+-specific circRNAs (n = 164) were found to 
overlap and/or neighbor 170 genes of which 129 cancer-related genes (p-value = 
2.28E-12–6.82E-03) were associated with estrogen receptor signaling, 
epigenetic signaling, and oxidative stress response pathways.  
 
 
Figure 12: Tumor-specific circRNAs common and unique to TN, ER+ and 
HER2+ subtypes and the top canonical pathways associated with each subtype. 
 
 
 
 
 
 
  50 
3.2.4.2 Paired normal-adjacent tissue analysis 
 
3.2.4.2.1 Normal-adjacent samples have more unique circRNAs than 
tumor samples in ER+ subtype 
We obtained paired breast tumor and normal-adjacent data from TCGA for 13 
TN, 56 ER+, and 20 HER2+ samples. The circRNA results showed that the 
normal-adjacent samples had a higher number of unique circRNAs than the 
matched tumors in 5/13 TN patients, 23/56 ER+, and 6/20 HER2+ samples. 
Using standard paired t-test, again we found that in ER+ cancer, number of 
circRNAs was higher in normal-adjacent than tumor with p-value < 0.027. No 
correlation was observed between number of unmapped reads and circRNA 
number (R2 = 0.099), and after normalizing for unmapped reads, we still 
observed significant difference (p-value < 0.041) between ER+ normal-adjacent 
tissue and tumor samples. The TN and HER2+ patients did not show 
significance, p-value > 0.05  and combining all subtypes (89 pairs) yielded p-
value < 0.1. 
 
A large number of circRNAs were observed in normal breast samples from GTEx 
data. To confirm that number of circRNAs observed in normal samples is higher 
than breast tumors, we analyzed an independent cohort of 218 normal breast 
mammary tissues from the GTEx project (http://www.gtexportal.org/home/). After 
normalizing for library size, we observed a higher number of circRNAs compared 
to all three TCGA breast subtypes (Figure 13). 
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Figure 13: Increased number of circRNAs in normal breast samples compared to 
breast tumor subtypes in TCGA. A legend from left to right – Gtex_female and 
Gtex_male represent female and male mammary tissues from the Gtex project; 
ER+, HER2+ and TN normal-adjacent and matched tumors from TCGA are 
represented by ER_norm_adj, ER_tumor, HER2_norm_adj, HER2_tumor, 
TN_norm_adj and TN_tumor respectively. 
 
 
Recently, Bachmayr-Heyda et al. [91] reported that total number of circRNAs is 
negatively correlated with tumor proliferation marker MKI67 in colorectal cancer. 
Here we used a collection of 11 genes: BIRC5, CCNB1, CDC20, CEP55, MKI67, 
NDC80, NUF2, PTTG1, RRM2, TYMS, and UBE2C that are signatures for 
proliferation and are also part of the PAM50 classification gene panel [97]. We 
calculated the risk-of-relapse proliferation score (ROR-P) [93] for these genes to 
see if they have similar negative correlations with breast cancer subtypes. 
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We observed that ER+ normal-adjacent tissue samples had a higher number of 
circRNAs and displayed lower levels of proliferation marker gene expression than 
ER+ tumor samples. Figure 14 is plotted between the ROR-P score and circRNA 
numbers for the tumor samples and indicates that the number of circRNAs in the 
ER+ tumors tends to decrease with average increase in gene proliferation. This 
trend is explained by a slightly negative correlation of −0.22. A corresponding 
analysis of paired HER2+ and TN samples revealed correlations of −0.15 in 
HER2+ and 0.24 in TN tumors. 
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Figure 14: Lower number of circRNAs as gene proliferation increases in ER+ 
tumor samples 
 
3.2.4.2.2 ER+ luminal A and luminal B tumor tissues have distinct 
proliferation patterns based on the number of circRNAs 
 
Because circRNAs appear to be promising markers for proliferation in ER+ 
tumors, and since a number of circRNAs were significantly different between 
normal-adjacent and tumors, (p-value < 0.027), we further investigated if they 
could distinguish between the luminal A and luminal B types, as luminal B tumors 
proliferate more rapidly. First, we used PAM50 centroid modeling to identify the 
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tumor and normal-adjacent Luminal A and B subtypes for TCGA ER+ samples. 
Next, using all matched tumor and normal-adjacent ER+ samples (56 pairs), we 
plotted the number of circRNAs with respect to tumor proliferation. A clear 
distinction between the two ER+ types was evident for the tumor samples (Figure 
15A). Luminal B tumors had fewer circRNAs (18 on average) than Luminal A 
tumors (25 on average) and this difference in circRNAs number was significant 
with p-value < 0.011 using Welch t-test. Luminal B normal–adjacent samples had 
a similar number of circRNAs to luminal A normal–adjacent samples –24 and 30 
on average, respectively, which was not statistically significant (p-value = 0.31). 
An unsupervised hierarchical clustering analysis, shown in Figure 15B, also 
indicated that tumor and normal-adjacent samples cluster separately based on 
their circRNA numbers. In addition, Luminal B tumors separated out into their 
own sub-cluster within the tumor arm. These results suggest that Luminal A and 
B tumor samples show distinct differences in terms of proliferation marker gene 
expression based on their circRNA numbers. We hypothesize that this measure 
may be of use for other cancers with heterogeneous subtypes. 
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Figure 15: (A) Luminal A and Luminal b tumor samples show distinct separation 
based on their circRNA numbers when plotted against tumor proliferation, (B) 
Unsupervised hierarchical clustering analysis shows separation of Luminal A and 
Luminal B tumor and adjacent samples based on their circRNA numbers. 
 
3.3 Methods 
 
3.3.1 Circ-Seq workflow 
 
The Circ-Seq workflow flowchart is represented in Figure 16. Circ-Seq is an 
extension of the circRNA detection methodology by Memczak et al. [16] and 
incorporates essential filters as well as a comprehensive annotation to the final 
list of circRNA candidates. Circ-Seq starts by fragmenting unmapped reads from 
the aligned transcriptome BAM file into short 20-mer anchors from their 5′ and 3′ 
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ends and are then realigned against the reference genome. For every unmapped 
read, if the anchor pair maps in a 3′ to 5′ fashion, the alignment is shortlisted as 
possible evidence for a circRNA. Next, acceptor and donor splice sites, i.e., AG 
and GT, are checked for the selected 3′ and 5′ anchors. The presence of anchors 
within the splice sites is treated as initial confirmation of the fusion of exons in a 
circRNA fashion. At this point, the workflow quantifies the number of anchors 
supporting each circRNA candidate. 
 
Next, three unique filters are applied to eliminate unexpressed and false-positive 
circRNAs: an expression filter, a genomic size filter, and a validation filter. The 
expression filter retains circRNA candidates supported by a sufficient number of 
junction-spanning reads and is set to 5 reads by default, which is considerably 
more stringent than existing approaches [16].The genomic size filter discards any 
candidates shorter than six bases. Finally, to ensure that circRNAs reported by 
the workflow are not identified from repetitive regions of the genome, the 
validation filter uses BLAT [51] to confirm that the 3′ (head) and 5′ (tail) 
coordinates of the circRNA represent unique locations of the genome. After 
completing the analysis, the workflow provides a circRNA quantification report 
and a FASTA file that contains 50-base nucleotide sequences containing the 3′–
5′ fused junction of all circRNAs identified. 
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Figure 16: Circ-Seq bioinformatics workflow flowchart. 
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3.3.2 TCGA breast cancer transcriptome data 
 
We downloaded 1,034 breast cancer RNA-Seq binary alignment map (BAM) files 
from the TCGA Research Network (http://cancergenome.nih.gov/) using the 
National Cancer Institute (NCI) Genomic Data Commons (GDC) resource 
(https://gdc.cancer.gov/). The un-stranded Illumina TrueSeq protocol was used to 
obtain 50 nucleotide paired-end reads from TCGA breast cancer RNA-Seq 
samples. The paired-end reads were then aligned using MapSplice v12_07 [43]; 
these reads contained both reads mapped to the human reference genome 
(hg19 / NCBI 37.1) and unmapped reads. 
 
3.3.3 TCGA breast tumor and normal-adjacent samples and 
normal breast mammary tissue from GTEx 
We obtained clinical metadata for the 1,034 breast cancer samples from the NCI 
GDC Data Portal (https://gdc-portal.nci.nih.gov/). Because TCGA continues to 
add breast cancer cases to its repository, the most recent number of breast 
cancer samples available from TCGA may be higher than the number used in 
this work. We first classified the samples into the three predominant molecular 
subtypes – TN, ER+, and HER2. Out of 1,034 samples, we were able to classify 
subtypes for 885 samples of which 561 were ER+, 141 were TN, and 183 were 
HER2+ samples.  
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We downloaded BAM files for 218 normal breast samples (126 male and 92 
female samples) from the Gtex project (http://www.gtexportal.org/home/) using 
Aspera client (http://asperasoft.com/). Samples were sequenced using Illumina 
TrueSeq paired-end RNA sequencing with read length 75 bp. The transcriptome 
BAM files that were downloaded for the 218 samples were aligned to the hg19 
reference genome using Tophat [59]. 
 
3.3.4 Breast cancer cell lines 
 
We also obtained RNA-Seq paired-end sequence files for six breast cancer cell 
lines (BT20, BT474, MCF7, MDAMB468, T47D, and ZR751) and one cell line 
derived from normal breast cells (MCF10A) [94]. Sequences from the cell lines 
were processed using the Mayo Analysis Pipeline for RNA Sequencing (MAP-
RSeq) to yield BAM files for use with the Circ-Seq workflow [37]. The number of 
unmapped reads for the cell lines varied from 5 to 22 million reads. 
 
3.3.5 Pathway analysis for tumor-specific circRNAs 
 
Gene names and annotations of genes that either overlap or neighbor tumor-
specific circRNAs were obtained using the Ensembl reference system (version 
GRCh37.75). Enriched canonical pathway analysis for tumor-specific circRNAs in 
the breast molecular subtypes was performed using the Ingenuity pathway 
analysis software IPA (Ingenuity® Systems, http://www.ingenuity.com). Biological 
functions and diseases information within the IPA software was used for critical 
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investigation of cancer-related pathways. Open source analysis toolkit 
WebGestalt [98] was also used to derive pathway results. 
 
3.3.6 CircRNA validation 
 
MCF7 breast cancer cells (American Type Culture Collection Manassas, VA) 
were cultured in EMEM medium containing 10% fetal bovine serum (FBS) at 
37ºC in 5% CO2. Total RNA and genomic DNA were isolated using the RNeasy 
Plus Micro Kit and DNeasy Blood & Tissue Kit (QIAGEN, Inc.,Valencia, CA) 
respectively. DNA and RNA quality was analyzed using the NanoDrop 8000 
spectrophotometer. qRT-PCR was performed with the Power SYBR® Green 
RNA-to-CTTM 1-Step Kit (AB, Foster, CA) using a Stratagene Mx3005P Real-
Time PCR detection system. GAPDH DNA and RNA were used as controls for 
the experiment. We designed two sets of primers, convergent primers that bound 
to linear 5′–3′ mRNA transcripts and divergent primers that bound to the circRNA 
transcript (chr14:102,466,325–102,500,789) formed in a 3′–5′ fashion, which 
were provided by Integrated DNA Technologies. After gel purification using the 
QIAquick Gel Extraction Kit (QIAGEN), the qRT-PCR product was sequenced 
using the Sanger method to confirm the head-to-tail splicing. 
 
 
 
 
  61 
3.4 Discussion 
 
In this study, using existing bioinformatics approaches defined by Memczak et al. 
[16] we developed a comprehensive analytical workflow called Circ-Seq. We also 
introduced three essential filters for identification and characterization of stable 
and expressed circRNAs in Circ-Seq. The workflow was designed with flexibility 
to allow users to configure these filters based upon their choice to report results 
that are either stringent or lenient. Circ-Seq is also designed with speed in mind. 
It is built to work on a multi-threaded cluster environment and can analyze 
numerous samples in parallel at any given time. 
 
Circ-Seq was applied to the transcriptome of 885 TCGA breast cancer samples, 
and we identified numerous circRNAs unique to breast tumors and normal-
adjacent tissues. To our knowledge, this is the first report to catalog circRNAs 
unique to the TN, HER2+, and ER+ molecular subtypes of breast cancer, as well 
as circRNAs common to all of the subtypes but absent from normal-adjacent 
tissue. Finally, using a panel of 11 tumor proliferation marker genes in 
combination with circRNA abundance, we show that circRNA number is 
associated with tumor proliferation and that luminal A and luminal B tumors have 
distinct representations of circRNA numbers within the ER+ breast molecular 
subtype. 
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We also identified circRNAs in the breast cell lines and were able to successfully 
validate the largest circRNA identified in MCF7 found at genomic location 
chr14:102,466,325–102,500,789 with 12 supporting junction reads. This circRNA 
was a spliced product of gene DYNC1H1 and spanned from exons 17 to 56 of 
the gene. Considering that the exon-intron structure remains intact, the size of 
this circRNA is about 7 kb and may play a role in post-transcriptional regulation. 
Notably, the circRNA contained microRNA response elements (MRE) for miR-
150 and miR-661 with 29 and 23 unique binding sites respectively. These two 
microRNAs have been previously reported to have associations with cancer [99, 
100]. In searching for other microRNAs that have over 20 binding sites, we found 
non-conserved microRNAs such as miR-3613, miR-4731 and miR-5095, each 
contains 25 MRE sites along the circRNA. It is possible that since the circRNA 
contains several binding sites for microRNAs, this could be a candidate player in 
breast cancer competing endogenous RNA (ceRNA) networks. 
 
Recent studies suggest that circRNAs have other functions that are more 
common than the microRNA sponge effect. Notably, circRNAs are shown to 
participate actively in pre-mRNA splicing [80] and also as active promoters of 
transcription of parent mRNAs [86]. We believe that the circRNAs reported in this 
study can also have implications similar to the above functions in breast cancer. 
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Although validation results suggest that the workflow reported legitimate 
circRNAs, the reliability of the workflow and the measure of the false positive rate 
can only be determined based on its application to more transcriptome datasets 
and validation of results in future. The number of unmapped reads is a key player 
in identifying circRNAs within a sample. We observed that unmapped reads for 
the breast tumor and non-tumor cell lines range was 5–22 million and the range 
for TCGA samples was 5–78 million. Samples with unmapped reads at the low 
end of the spectrum can likely have a correspondingly low number of circRNAs 
reported. We hypothesize that the number of circRNAs identified for BT20, T47D, 
MCF7, and MCF10A was artificially low due to the small number of unmapped 
reads available for these samples. 
 
One of the limitations of this study is that the RNA-Seq libraries from TCGA are 
prepared using Illumina TruSeq, which enriches for poly-A tail transcripts [101], 
thus substantially limiting the number of circRNAs detected. Despite this 
limitation, we identified large numbers of circRNAs in the TCGA breast cancer 
data. Stranded total RNA and RiboMinus libraries may improve the detection of 
circRNAs [16, 72, 73, 82, 84, 87]. We acknowledge that the circRNAs identified 
here are only a small subset of the actual population of the circRNAs present in 
breast cancer samples. Because the number of circRNAs detected increases 
with the number of samples investigated, as shown in Table 6, the number of 
circRNAs detected for the TN, and HER2+ subtypes are probably 
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underestimated due to their smaller sample size. This could also be indicative of 
why we observed poor correlations and non-significant probability measures for 
these subtypes when the corresponding associations always held true for ER+ 
samples. Likewise, it is uncertain at this point whether the tumor proliferation 
analysis for TN and HER2+ patients with matched tumor and normal-adjacent 
tissues would indeed have a negative correlation with circRNA numbers or not, if 
an adequate number of samples were available for these subtypes. 
 
Taking together the biological complexities of cancer, individual RNA classes 
cannot be considered in isolation. Cooperative communication between different 
types of noncoding RNAs and protein-coding genes or mRNAs exists [23, 25, 
102, 103] which eventually tune the expression of target genes. In cancer, 
regulated expression of tumor suppressors and oncogenes is critical to 
tumorigenesis. Competing endogenous RNA networks comprising of complex 
interactions between mRNA, microRNA and circRNA molecules can greatly 
influence the post-transcriptional activity of such genes. MRNA stability, or lack of 
stability—depending on how the circRNAs and microRNAs interact via microRNA 
binding sites—can significantly impact gene expression, with serious 
repercussions for tumorigenesis. Innovative and ingenious bioinformatics 
techniques need to be developed that can unravel ceRNA crosstalk between 
such RNA types and eventually lead to novel findings which can be used as 
potential diagnostic targets to improve treatment of cancer. It is possible that the 
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findings that emerge from the study of circRNAs will lead to improvements in the 
diagnosis and treatment of complex, heterogeneous diseases such as cancer. 
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Chapter 4: ReMIx - A novel bioinformatics 
approach to integrate mRNA-microRNA 
interactions using MRE frequencies from RNA-
Seq data 
 
4.1 Introduction  
 
 
The transcriptome activity in a tumor or normal cell involves complex interactions 
between mRNAs (mRNAs) and other coding and non-coding RNAs that greatly 
influence the post-transcriptional availability of genes in the cell. One such 
interaction, which has shown to have enormous implications in cancer, is the 
interaction between mRNAs and microRNAs [26, 28, 104]. MicroRNAs regulate 
gene expression by using their seed sequences (6 - 8 bases long) to bind to the 
microRNA response element (MRE) sites located on the 3’ untranslated regions 
(3’ UTR) of mRNAs. Genes can have one or more distinct MRE sites, thus being 
targets to multiple microRNAs, and likewise, microRNAs can bind to MRE sites of 
several different gene targets [105, 106]. Most of the times microRNAs bind 
partially, and sometimes entirely, to MRE sites of their target leading to 
suppressed translation or mRNA degradation. Lately, it has been shown that 
non-coding circRNAs (circRNAs) also contain conserved binding sites for 
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microRNAs and thus can function as critical post-transcriptional regulators [16]. 
CircRNAs can use their MRE binding sites to compete with mRNAs for a shared 
pool of microRNAs. For heterogeneous diseases such as cancer, it is critical to 
understand how complex interactions between mRNAs, circRNAs, and 
microRNAs impact the levels of target mRNA expression in the tumor. The 
mRNAs belong to diverse biological pathways and thus alterations in target gene 
expression via microRNA binding as well as regulation via circRNA competition 
can impact several cellular processes, such as cell cycle, proliferation, cell death, 
apoptosis, etc., during cancer development, progression and migration. Thus, 
finding key players among the mRNA-microRNA-circRNA interacting networks 
can yield identification of new biomarkers in cancer, especially for cancer 
subtypes that are least responsive to current modalities of treatment.  
 
 
 Eminent advancement in NGS technologies has allowed consortia such as The 
Cancer Genome Atlas (TCGA) to sequence large populations of cancer patients 
and to make data available for research. Studies have used microRNA and 
mRNA expression profiles across many cancer types in TCGA to infer 
microRNA-target interactions that could be active and functional in different 
cancer types [107]. Other studies have looked into alternative polyadenylation of 
3’UTRs in TCGA bladder cancer to show how short 3’UTR lengths affect mRNA 
stability and attenuate protein translation [108]. There have also been focused 
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analyses of SNPs present at 3’UTR regions of genes that affect microRNA 
binding and are shown to be associated with multiple cancer subtypes [109]. 
However, no work has been done so far to extrapolate TCGA RNA-Seq data 
alone to analyze MRE sites across the transcriptome of the tumor and normal 
samples to obtain insights into unique interactions between mRNAs and 
microRNAs at the 3’ UTR regions in the tumor. 
 
Here we present a new bioinformatics approach called ReMIx (pronounced 
“remix”) – mRNA-MicroRNA Integration, that leverages RNA-Seq data to quantify 
microRNA binding sites (MREs) at the 3’ UTR of genes across the transcriptome. 
ReMIx quantitates MRE sites in tumor and normal separately, which later 
enables identification of differentially expressed MREs that are statistically 
significant in the tumor. Since MRE is the link between mRNAs and microRNAs, 
ReMIx effectively reports candidate mRNAs and microRNAs that have a 
differential pattern of binding in the tumor. Additionally, based on our previous 
work in circRNAs [38], we also integrated circRNA transcripts for mRNAs with 
differential tumor MRE sites. Finally, bringing together a) mRNAs with tumor-
specific MRE sites, b) microRNAs that have the potential to bind to these MRE 
sites, and c) circRNA transcripts for these targets, ReMIx reports potential 
mRNA-miRNA-circRNA candidates that have unique interactions specific to the 
tumor. The method can be applied to study any cancer subtype of complex 
disease with tumor/affected and normal sequencing datasets. As an example, 
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here we have shown the application of ReMIx method to TCGA RNA sequencing 
data [110, 111] for Triple Negative  Breast  Cancer (TNBC) cases, normal-
adjacent tissues, along with  ER+ and HER2+ tumors, to identify ReMIx 
candidates unique to the TNBC tumors. Our analysis of the TCGA breast cancer 
cohort has identified promising targets for better diagnosis and treatment of 
TNBC disease.  
 
4.2 Results 
 
 
4.2.1 Application of ReMIx to triple-negative tumor and normal-
adjacent pairs 
 
The RNA-Seq aligned BAM files for 13 pairs (Tumor and Normal-Adjacent) cases 
from TN subtype, 56 pairs of ER+ subtype and 20 pairs of HER2+ subtype were 
obtained from the MAPR-Seq workflow [37]. These BAM files were further subset 
to 3’ UTR regions of individual genes (n=12,455 as per TargetScan v7.0) and 
converted to fastq format for input to the ReMIx workflow (see Methods). The 
pre-computed MRE sequences (n=329 microRNA seeds, as per TargetScan 7.0) 
were also provided as input to FIMO [112] to report a read count for individual 
MREs located on every gene. The MRE counts were then normalized by 
factoring the library size, 3’UTR lengths and 3’UTR GC content of individual 
genes. Since genes can contain multiple MRE sites, at the end of the MRE 
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quantification process, we obtained normalized counts for a total of 111,522 MRE 
sites in tumor and normal-adjacent samples separately, for each subtype.  
 
Next, we sought to identify MRE sites that had unique and significant levels of 
expression (high or low)  in the TN tumor cases when compared to ER+ tumors, 
HER2+ tumors as well as TN, ER+ and HER2+ normal-adjacent cases. Using 
Dunnett-Tukey-Kramer pairwise multiple comparison statistical test on these 
tumor and normal-adjacent cases across all subtypes (total of 6 groups), we 
found 614 TN tumor-specific MRE sites that were significant at p-value < 0.05. As 
shown in Figure 17, we observed that more than half of the 614 MRE sites had 
lower expression in TN tumors when compared to other subtypes as well as TN 
normal-adjacent cases.  
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Figure 17: Heatmap of 614 TN-tumor specific MREs. The normalized CQN 
values of 614 MREs were obtained for TN, ER+ and HER2+ tumors and normal-
adjacent (norm-adj) cases. As shown in the heatmap, these MREs have a 
distinct expression in TN tumors in comparison to the other subtypes as well as 
TN normal-adjacent cases.  
 
4.2.2    614 MREs associated to 272 genes and 198 microRNAs  
 
 Since one MRE site is the combination of a gene and microRNA, the 614 TN 
tumor-specific MRE candidates were de-coupled to identify the respective genes 
and microRNAs. We obtained 272 genes and 198 microRNAs that were 
associated with these MREs. The heatmaps in Figure 18 represent the 
expression of the 614 MREs (CQN normalized values), 272 genes (RPKM values 
obtained from RNA-Seq data) and 198 microRNAs (CPM values obtained from 
microRNA-Seq data) for the 13 Triple-Negative Tumor and Normal-Adjacent 
samples. Un-supervised hierarchical clustering showed that the samples 
clustered well within their Tumor and Normal-Adjacent groups for all three data 
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types. Differential patterns of expression for the 614 MREs were also reflected in 
the heatmaps for the 272 genes and 198 microRNAs.  
 
 
Figure 18: Un-supervised clustering and heatmap representation 614 TN-tumor 
specific MREs and their associated genes and microRNAs. The 614 MREs were 
associated with 272 genes and 198 microRNAs. CQN normalized values were 
obtained for the MRE sites. Likewise, RPKM normalized values from RNA-Seq 
and CPM normalized values from microRNA-Seq were obtained for these 13 
pairs of TN tumor and normal-adjacent cases to generate their respective 
heatmaps. Unsupervised clustering of the cases indicates that tumor (purple) and 
normal-adjacent (cyan) were clustered well within their groups. 
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So far, based on MRE sites, we found that 272 genes showed evidence of 
differential expression at their MRE sites (614 MREs) for the TN tumors. Next, 
we were curious whether this MRE expression change for the 272 genes would 
continue to be reflective at the gene level and if they would still be distinct for the 
TN tumors when compared to other subtypes. For this we used RNA-Seq gene 
expression data for the TCGA cases (13 TN pairs, 56 ER+ pairs, and 20 HER2+ 
pairs) and found that, when looking across the ER+ and HER2+ subtypes, not all 
but a subset of the 272 genes still had high as well as low expression that was 
distinct to the TN tumors, as shown in Figure 19. 
 
Figure 19: Heatmap of gene expression for 272 genes. Using supervised 
clustering, the RPKM normalized values were plotted for 272 genes from TN, 
ER+ and HER2+ subtypes. The heatmap indicates that a subset of these genes 
have different expression profiles in TN tumors when compared to other 
subtypes and normal-adjacent cases. 
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4.2.3    MAPK and PI3K-AKT signaling identified among top 
pathways  
 
The 272 genes obtained from MRE analysis were further analyzed to identify 
their associated canonical pathways. Using gene set enrichment analysis 
(GSEA) [113] on KEGG and REACTOME databases, we found the mitogen-
activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K-AKT) 
signaling cascades reported among the top significant pathways. Additionally, 
application of the Signaling Pathway Impact Analysis (SPIA) package also 
reported MAPK signaling pathway to be activated in these TN tumors.  
 
Closer examination of the genes in the MAPK and PI3K-AKT pathways revealed 
that among several genes that were activated and repressed, oncogenes KRAS, 
NRAS, AKT, and NFKB were notably activated and tumor suppressor PTEN was 
repressed in the MAPK and PI3K-AKT pathways. Figures 20 and 21 illustrate the 
respective KEGG pathway diagrams for MAPK and PI3K-AKT signaling 
cascades. 
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Figure 20: MAPK signaling pathway. Genes in the pathway are colored based on 
their expression in TN tumors. Oncogenes NFKB and AKT are notably activated 
in this pathway. 
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Figure 21: PI3K-AKT signaling pathway. Genes in the pathway are colored 
based on their expression in TN tumors. Oncogenes PI3K, Ras, and AKT found 
activated and tumor suppressor PTEN repressed in this pathway. 
 
 
 
MAPK and PI3K-AKT signaling pathways are huge network cascades with 
connections to several essential biological pathways downstream such as 
proliferation, cell cycle, glycolysis, apoptosis, protein synthesis, etc. As a result, 
these cascades comprise of large number of genes involved in conducting and 
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maintaining activities within the MAPK and PI3K-AKT pathways. From our MRE 
analysis, we know the gene-microRNA pairs that formed the 614 MRE sites that 
are distinct to TN tumors. We therefore investigated the relevant gene-microRNA 
pairs that were part of the MAPK and PI3K-AKT pathways. This information is 
tabulated in Table 7, where we found that 12 out of 294 genes (~ 4%) in the 
MAPK pathway and 13 out of 351 genes (~4%) in the PI3K-AKT pathway have 
MRE sites that have potential for differential binding of microRNAs in TN tumors. 
The microRNAs that bind to these differential MRE sites for respective genes are 
also provided in Table 7. 
 
mRNAs microRNAs 
MAPK signaling pathway 
CACNA2D1 hsa-miR-429 
PPP3CB hsa-miR-330-5p; hsa-miR-486-5p 
RASGRF1 hsa-miR-384 
IGF1 hsa-miR-142-5p; hsa-miR-488-3p 
HGF hsa-miR-495-3p 
EFNA5 hsa-miR-101-3p.2; hsa-miR-130b-3p; hsa-miR-489-3p; hsa-miR-96-5p 
PDGFRA hsa-miR-132-3p; hsa-miR-140-5p; hsa-miR-491-5p 
FOS hsa-miR-802 
TGFBR2 hsa-miR-361-5p; hsa-miR-665 
FLNC hsa-miR-377-3p 
ARRB1 hsa-miR-140-3p.1; hsa-miR-296-5p 
PPM1A hsa-miR-488-3p 
PI3K-AKT signaling pathway 
DUSP1 
hsa-miR-141-3p; hsa-miR-144-3p; hsa-miR-194-5p; hsa-miR-379-3p; hsa-
miR-411-5p.1; hsa-miR-495-3p 
IGF1 hsa-miR-142-5p; hsa-miR-488-3p 
HGF hsa-miR-495-3p 
EFNA5 hsa-miR-101-3p.2; hsa-miR-130b-3p; hsa-miR-489-3p; hsa-miR-96-5p 
PDGFRA hsa-miR-132-3p; hsa-miR-140-5p; hsa-miR-491-5p 
GHR hsa-miR-129-5p; hsa-miR-132-3p; hsa-miR-505-3p.2 
COL1A1 hsa-miR-129-5p;hsa-miR-133a-3p.2  
THBS2 hsa-miR-182-5p; hsa-miR-379-3p 
ITGA1 hsa-miR-27a-3p 
PIK3R1 hsa-miR-126-3p.2; hsa-miR-361-5p; hsa-miR-455-3p.1; hsa-miR-488-3p; 
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hsa-miR-493-5p 
LPAR1 hsa-miR-142-3p.2 
GNB4 hsa-miR-29a-3p; hsa-miR-381-3p 
PTEN hsa-miR-140-3p.2 
 
Table 7: Gene-microRNA pairs with distinct TN-specific MRE sites that are part 
of the MAPK and PI3K-AKT pathways. This table lists genes that are a subset of 
the 272 genes obtained from the MRE analysis, which are members of the MAPK 
and PI3K-AKT signaling pathways. The microRNAs that bind to the MRE sites 
which were found to have distinct counts in TN tumors are also provided. 
 
 
 
4.2.5 CircRNAs associated with MAPK and PI3K-AKT pathways 
 
Based on our previous work in TCGA breast cancer [38], we identified several 
circRNAs in TN breast tumors. The Circ-Seq workflow classified circRNAs as 
inter-gene and intra-gene circRNAs (based on genomic coordinates), and in this 
study, we focused on intra-gene circRNAs, which were annotated as circular 
transcripts formed from a single gene. We were curious if there was any 
evidence of circRNAs for the genes involved in the MAPK and PI3K-AKT 
pathways and found that indeed, a subset of genes also contained evidence of 
circular transcripts. Table 7 presents the candidate intra-gene circRNAs that 
were identified and the corresponding genes they are associated with, in the 
MAPK and PI3K-AKT signaling pathways.  
 
circRNA Average 
expression 
in TN 
tumors 
Gene  
(activated –A, 
repressed – R in 
TN tumors) 
circRNA type 
MAPK signaling pathway 
circ_PRKACB 3 PRKACB (R) Tumor 
circ_ANGPT1 5 ANGPT1 (R) Tumor 
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circ_MYC 1.73 MYC (R) Tumor 
circ_STMN1 5 STMN1 (A) Tumor 
circ_TGFB1 1.75 TGFB1 (A) Tumor 
circ_RAC1 1.64 RAC1 (R) Tumor-Specific 
circ_IRAK1 1.53 IRAK1 (A) Tumor-Specific 
circ_MAP3K7 1.91 MAP3K7 (A) Tumor 
circ_MAPK13 3 MAPK13 (A) Tumor 
circ_DUSP16_1 2 DUSP16 (R) Tumor 
circ_DUSP16_2 3 DUSP16 (R) Tumor 
circ_NR4A1 1.5 NR4A1(R) Tumor-Specific 
circ_RELA 6 RELA (A) Tumor 
PI3K-AKT signaling pathway 
circ_ANGPT1 5 ANGPT1 (R) Tumor 
circ_RAC1 1.64 RAC1 (R) Tumor-Specific 
circ_FN1 1.61 FN1 (A) Tumor 
circ_SPP1 1.43 SPP1 (A) Tumor 
circ_TNC 1.67 TNC (R) Tumor-Specific 
circ_ITGB3 7 ITGB3 (R) Tumor 
circ_DDIT4 1.71 DDIT4 (A) Tumor-Specific 
circ_PPP2R1A 2.2 PPP2R1A (A) Tumor 
Circ_COL1A1 2.3 COL1A1 (A) Tumor-Specific 
circ_PPP2R5E 3 PPP2R5E (R) Tumor 
circ_HSP90B1 2.55 HSP90B1 (A) Tumor 
circ_CRTC2 1.44 CRTC2 (A) Tumor 
circ_GSK3B 12 GSK3B (A) Tumor 
circ_G6PC3 1.71 G6PC3 (R) Tumor-Specific 
circ_MYC 1.73 MYC (R) Tumor 
circ_CCND2 5 CCND2 (R) Tumor 
circ_MCL1 1.47 MCL1 (R) Tumor 
circ_NR4A1 1.5 NR4A1 (R) Tumor-Specific 
circ_RELA 6 RELA (A) Tumor 
 
Table 8: Intra-gene circRNAs identified in MAPK and PI3K-AKT pathways. 
Circular transcripts obtained from the Circ-Seq workflow on TCGA TN breast 
cancer cases were used to identify intra-gene circRNAs associated with genes in 
the MAPK and PI3K-AKT pathways. CircRNA type ‘Tumor-Specific’ denotes that 
the circRNA was found only in TN Tumors, whereas circRNA type ‘Tumor’ 
indicates that there is a different circRNA isoform in the reported gene was found 
in TN normal-adjacent.   
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4.2.6 mRNA-microRNA-circRNA interacting candidates in MAPK 
and PI3K-AKT pathways for TN breast cancer 
 
Based on the mRNA-microRNA results from the ReMIx methodology as well as 
the circRNAs from Circ-Seq workflow, we expanded the MAPK and PI3K-AKT 
pathways in the TN tumors by including the interacting non-coding microRNAs 
and circRNAs that, based on our results, are also essential members of these 
pathways. Figures 22 and 23 represent the MAPK and PI3K-AKT endogenous 
RNA networks with both protein-coding and non-coding RNAs that are likely to 
interact with each other and regulate expression of the central mRNAs, such as 
oncogenes PI3K, AKT, Ras, NFKB and tumor suppressor PTEN.  
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Figure 22: MAPK endogenous RNA network. This figure shows the network 
of interacting protein-coding and non-coding genes in the MAPK singling 
pathway. The mRNAs and microRNAs reported by ReMIx are represented in 
colors orange and blue, respectively. Intra-gene circRNAs are represented 
in green color. Oncogenes AKT, RAS, NF-kB, PI3K, ERK and MEK are 
shown to interact either directly or indirectly with the mRNA-microRNA-
circRNA candidates. 
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Figure 23: PI3K-AKT endogenous RNA network. This figure illustrates the 
network of interacting protein-coding and non-coding genes in the PI3K-
AKT singling pathway. The mRNAs and microRNAs reported by ReMIx are 
represented in colors orange and blue, respectively. Intra-gene circRNAs 
are represented in green color. Oncogenes AKT, RAS, NF-kB and PI3K as 
well as tumor suppressor PTEN are shown to interact either directly or 
indirectly with the mRNA-microRNA-circRNA candidates. 
 
 
At the end, by including the interacting mRNAs, microRNAs and circRNAs and 
further expanding the MAPK and PI3K-AKT signaling pathways, we believe that 
we have identified a set of protein-coding and non-coding RNAs that have the 
potential to influence and modulate the overall expression of these pathways.  
Based on further analysis using expression-correlation methods, we trust the 
possibility of finding candidate RNAs can be promising diagnostic targets towards 
improving current treatment modalities in TN breast cancer patients. 
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4.3 Methods 
 
4.3.1 ReMIx – a novel methodology to compute MRE frequency 
from RNA-Seq data 
 
Here we present an innovative bioinformatics approach called ReMIx, which was 
used to quantify MRE sites at the 3’UTR regions of mRNAs from RNA-Seq data. 
This methodology, called ReMIx, uses reads aligned to the 3’UTR and scans 
them for evidence of any given MRE sequence. MRE sequences, which are 
complimentary to the seed sequences of microRNAs, are searched in the 3’UTR 
aligned reads of genes that are known to be associated with microRNAs (based 
on TargetScan – human version 7.0 [114]). A hypothetical example of this 
approach is illustrated in Figure 22. The reads aligned to 3’UTR regions of genes 
Gene A and Gene B are shown in Tumor and Normal-Adjacent samples. Gene A 
contains two MRE sites, and Gene B has one MRE site, with a common site 
(MRE1) in both genes.  The number of reads mapped to these MRE sites are 
quantified for each gene and tabulated separately for Tumor and Normal-
Adjacent samples. Later, MRE counts per gene are normalized and statically 
evaluated to identify differentially expressed MREs for downstream analysis.   
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Figure 24: Hypothetical representation of MRE frequency counting using RNA-
Seq data. The example shows a Tumor and Normal-Adjacent sample with reads 
mapped to the 3’ UTRs of two genes, Gene A and Gene B that consist of 2 and 1 
MRE sites respectively, with a common site (MRE 1). Reads that align with 
individual MRE sites (vertical dotted lines) are quantified. For every MRE site that 
belongs to a gene, the counts are then statistically evaluated between Tumor and 
Normal-Adjacent for evidence of differential frequency (as shown in the table). 
 
 
 
 
 
4.3.2 MRE frequency analysis from RNA-Seq data 
 
Seed sequences for all the conserved microRNA families (n=320) were 
downloaded from TargetScanHuman 7.1, and the corresponding complementary 
MRE sequences were derived using in-house bioinformatics scripts. Figure 23 is 
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a flowchart representation of the bioinformatics methodology behind ReMIx, 
developed for MRE frequency analysis.   
 
Figure 25: Flowchart representation of MRE frequency quantification from RNA-
Seq BAM. The RNA-Seq BAM is first subset to 3’UTR regions of all genes, 
converted to FASTQ and then processed through FIMO to obtain raw MRE 
counts per microRNA for every target gene. The raw MRE counts are normalized 
to account for library size, 3’UTR length and 3’UTR GC content and individual 
Tumor and Normal-adjacent quantification reports are generated. 
 
 
First, the RNA-Seq BAM files for both Tumor and Normal-Adjacent were subset 
to the 3’UTR regions for all genes using the SAMTools suite [58], thereby 
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obtaining one BAM per gene. Second, the newly obtained BAM files were 
converted into a FASTQ format so that for every gene, we had a collection of all 
reads that were mapped to their 3’UTR regions. BAM to FASTQ conversion was 
achieved using the bam2fastx module from Tophat [59].  Third, using the 
complementary seed (or MRE) sequences of individual microRNAs and the 
FASTQ files for corresponding genes that are known targets of these 
microRNAs, we quantified the occurrence of each MRE site by utilizing the motif 
searching bioinformatics tool called Find Individual Motif Occurrences (FIMO) 
[112]. Briefly, FIMO is an efficient and statistically rigorous software tool that 
scans nucleotide or protein sequences for the occurrence of a motif, or in this 
case, a MRE sequence. FIMO evaluates the occurrence of the MRE against a 
background frequency of nucleotides present in the hg19/NCBI 37.1 human 
reference genome and computes a log-likelihood ratio score. These scores are 
then converted to p-values, indicating whether the occurrence was a statically 
significant observation or not.  The output from FIMO is a table indicating the 
number of occurrences per MRE and their associated p-values. MRE sites with 
p-value < 0.05 were selected from the FIMO output for downstream processing. 
Fourth, the raw MRE counts were normalized to account for the differences in 
library size/sequencing depths as well as the 3’ UTR length and 3’ UTR GC 
content per gene. Finally, for every gene and every conserved microRNA that 
targets the gene, the normalized MRE counts were reported in a tab-delimited 
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format for each gene-microRNA pair in the Tumor and Normal-Adjacent cases 
separately. 
 
4.3.3 3’UTR definitions obtained from TargetScan 
 
Recently, Dr. David Bartel’s group developed an improved quantitative model to 
predict canonical targeting of microRNAs to 3’UTR regions of mRNA [114]. A 
combination of 14 features in the model coupled with experimental approaches 
such as poly(A)-position profiling by sequencing called 3P-seq was used to 
define 3’UTR positions of genes in the transcriptome accurately. This data, 
available at the TargetScanHuman 7.1 database, is what was used for 3’UTR 
definitions of genes in the MRE analysis study.  
 
4.3.4 RNA-Seq and microRNA-Seq data from TCGA 
 
The RNA-Seq binary alignment map (BAM) files and the microRNA Sequencing 
fastq files for the Triple Negative Tumor and Normal-Adjacent paired cases were 
downloaded from the TCGA Research Network (http://cancergenome.nih.gov/) 
using the National Cancer Institute (NCI) Genomic Data Commons (GDC) 
resource (https://gdc.cancer.gov/). The RNA-Seq BAM files were then converted 
to fastq files and aligned to the hg19/NCBI 37.1 human reference genome using 
the MAP-RSeq workflow [37]. The microRNA fastq files were aligned to the same 
human genome build using the CAP-miRSeq workflow [115].The normalized 
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microRNA counts from the workflow were used to obtain the microRNA 
expression values in the Triple Negative samples. The unmapped reads from the 
RNA BAM files obtained from MAP-RSeq [37] were further processed through 
the Circ-Seq workflow [38] to identify and annotate stable and expressed 
circRNAs for all the Triple Negative Tumor and Normal-Adjacent samples. 
 
4.3.5 Statistical analyses on MRE sites and activated pathway 
identification 
 
Evaluation of MRE sites that represented distinct counts specific to TN tumors as 
opposed to ER+ and HER2+ subtypes as well as TN normal-adjacent pairs were 
obtained using the R package Dunnett-Tukey-Kramer Pairwise Multiple 
Comparison Test Adjusted for Unequal Variances and Unequal Sample Sizes. 
MRE sites significantly associated with TN tumors were selected based on a p-
value cut-off < 0.05. Identification of the relevance and activation/inhibition status 
of pathways was evaluated using the R package called Signaling Pathway 
Impact Analysis (SPIA).  
 
 
 
4.3.6 Pathway analysis for canonical pathways 
 
Enriched canonical pathway analyses for 272 genes with differential MRE counts 
in TN breast tumors were identified using KEGG and Reactome functional 
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databases. Open source analysis toolkit WebGestalt [98] was used to for 
pathway identification by using the Gene set enrichment analysis (GSEA) option.   
 
4.4 Discussion 
 
In this study, we developed an innovative bioinformatics methodology called 
ReMIx that uses RNA-Seq data to identify and quantify microRNA binding sites 
or MREs at 3’UTR regions of genes. We applied this methodology to TCGA 
paired tumor and normal-adjacent breast cancer cases for TN, ER+, and HER2+ 
molecular subtypes and identified 614 MRE sites that had a distinct expression in 
TN tumors only. Majority of these sites had lower expression in TN tumors. Upon 
de-coupling, we found that the 614 MRE sites corresponded to 272 genes and 
198 microRNAs. Canonical pathway analysis revealed that the top significant 
pathways in these TN tumors were MAPK and PI3K-AKT signaling cascades. 
About 4% of gene members in these pathways were represented by genes we 
obtained from the MRE analysis. Based on our previous work in circRNAs in 
TCGA breast cancer [38], we found a number of intra-gene circRNAs that were 
associated with genes in the MAPK and PI3K-AKT pathways. Based on our 
results from this study, we provide a list of potential mRNA-microRNA-circRNA 
candidates that are likely to interact with each other at the network level of MAPK 
and PI3K-AKT signaling cascades and could be possible targets for identification 
of novel biomarkers in TN tumors. 
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One of the limitations of this study is that while ReMIx enables identification of 
candidate mRNA and microRNA players via MRE analysis using RNA-Seq data, 
this does not establish the fact that the identified microRNAs are indeed present 
and expressed in the particular disease, in this case, TN tumors. ReMIx results 
only confirm that the sites on 3’UTR of mRNAs where microRNAs bind to, show 
distinct expression profiles in tumor and thus have the potential to be regulated 
by microRNAs in a disease-specific manner. To complement these results, 
microRNA expression profiles can be used to validate the existence of 
microRNAs and to check for expression correlation with the corresponding 
mRNA target(s) identified by ReMIx.  
 
The libraries for the TCGA RNA-Seq samples were prepared using Illumina’s 
TruSeq library preparation protocol [110, 111]. One significant advantage of this 
protocol is that mRNAs are selected using poly-A enrichment. This enables pull-
down of not just coding features of genes, but also 3’ UTRs, to which poly-A tails 
are attached. While studies have utilized RNA-Seq to look into alternatively 
spliced 3’UTRs [116] and examine the impact of expressed variants present in 
the 3’UTR of genes [117, 118], no work has been done to date to extrapolate 
RNA-Seq data alone and obtain insights into the interactions between mRNAs 
and microRNAs at these 3’ UTR regions.  
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Lately, there has been much focus in research to explore and identify therapeutic 
strategies to better treat Triple Negative breast cancer patients and improve their 
chances of survival. It has been shown that activation of the MAPK and PI3K-
AKT pathways result in cancer cell proliferation and survival in the tumor [119]. 
Previous studies have shown these pathways to be highly prevalent in TN breast 
cancer as opposed to other breast cancer subtypes [120-122], thus supporting 
our findings. Studies have also shown that activation of MAPK [122-127] and 
PI3K-AKT [122, 128-134] pathways significantly correlate with tumor proliferation 
and disease progression in TN tumors.  MAPK pathway is a sequentially 
activated cascade consisting of key genes such as Ras, Raf, MEK, and ERK. 
Activation of Ras leads to phosphorylation of Raf thereby advancing into 
activation of MEK and ERK downstream, finally resulting in tumor proliferation 
and cell survival. The PI3K-AKT pathway is yet another signaling cascade where 
kinase PI3K is the central driver of oncogenic transformation and plays a 
fundamental role in proliferation and tumor survival. PI3K activates oncogene 
AKT that modulates downstream signaling pathways such as mTOR. The end 
result is inhibition of apoptosis and increased cell proliferation. 
 
Pre-clinical experiments have shown that MAPK and PI3K-AKT pathways have 
significant cross-talk and that inhibition of one cascade activates the other, and 
vice versa [119]. Thus, pre-clinical trials are underway that focus on co-targeting 
both pathways to improve clinical outcomes [119]. At present, clinicaltrials.gov 
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lists identifiers NCT01623349 (active), NCT03337724 (not yet recruiting), 
NCT03218826 (not yet recruiting) and NCT01629615 (completed) as trials that 
are investigating the effect of various PI3K drug inhibitors in Triple Negative 
patients. We believe that upon further evaluation and validation of our current 
mRNA-microRNA-circRNA results in this study, there is a potential to identify 
novel biomarkers, especially circRNA and microRNA candidates that interact with 
mRNA targets and regulate their gene expression in MAPK and PI3K-AKT 
pathways. 
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Chapter 5: Conclusions and Discussion 
 
 
 
RNA-Seq is a significant breakthrough in Next Generation Sequencing 
technology and has become the standard in bioinformatics for analysis of the 
transcriptome. The vast wealth of information offered by RNA-Seq helps uncover 
not only numerous features of protein-coding regions but also non-coding regions 
that are expressed in the transcriptome. There are many stand-alone 
bioinformatics packages which analyze different aspects of the transcriptome. 
However, they cannot be plugged together quickly, and they do not provide a 
complete, integrated picture. In addition, the field of bioinformatics lacks simple-
to-use workflows that can comprehensively analyze several features of the 
transcriptome together, and report in an integrated fashion. The first half of this 
dissertation offers bioinformatics solutions to address the above challenges. 
 
Chapter 1 is an introduction to the various RNA types in the human 
transcriptome that are studied in this dissertation, namely – mRNAs (protein-
coding), microRNAs and circRNAs (both non-coding). The unique interaction 
between these RNA types as well as the possible implications of these 
interactions in the etiology of diseases such as breast cancer is outlined in this 
chapter. Existing bioinformatics challenges are identified, and the motivation to 
address these is established by listing the three main specific aims that are 
pursued in this dissertation. 
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Chapter 2 presents a comprehensive bioinformatics workflow called MAP-RSeq 
[37] that was developed to both analyze and obtain several features of protein-
coding regions in the transcriptome. MAP-RSeq consists of six major modules 
such as alignment of reads, quality assessment of reads, gene expression 
assessment and exon read counting, identification of expressed single nucleotide 
variants (SNVs), detection of fusion transcripts, and summarization of 
transcriptome data in a final report.  
 
Chapter 3 presents a bioinformatics workflow called Circ-Seq [38] that was 
developed to characterize circRNAs, which are newly discovered and highly 
stable forms of non-coding RNAs with diverse biological functions. Circ-Seq 
consists of five major modules such as alignment of unmapped reads, 
identification of circRNA junctions, application of circRNA specific filters and 
extensive genomic annotation of expressed circRNA candidates, all summarized 
in a final report.  
 
Circ-Seq can be used seamlessly after MAP-RSeq, and at the end of both 
workflows, researchers can quickly and efficiently acquire information on various 
perspectives of protein-coding mRNAs and non-coding circRNAs without 
spending time and effort in dealing with multiple stand-alone packages and 
integrating results across them.  
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In this dissertation, MAP-RSeq and Circ-Seq workflows were applied to the 
largest cohort of breast cancer (n=885 samples) from The Cancer Genome Atlas 
(TCGA) as well as breast cancer and breast normal cell lines. MAP-RSeq results 
were used to obtain gene expression profiles across all three molecular subtypes 
– ER+, HER2+, and TN, of breast cancer. By applying the Circ-Seq workflow and 
analyzing the results, we reported for the first time in breast cancer research, the 
identification and annotation of a 7kb long circRNA, which was experimentally 
validated in the MCF7 breast cancer cell line using qRT-PCR and Sanger 
sequencing. In addition, comprehensive analysis of circRNAs in TCGA ER+ 
breast cancer subtype suggested that circRNA frequency may be a marker for 
cell proliferation in breast cancer.  
 
Complex interactions between mRNAs, circRNAs, and microRNAs can greatly 
influence post-transcriptional activity in the cell. For heterogeneous diseases 
such as breast cancer, it is of paramount value to understand such interactions 
and elucidate the key players that cause ultimate changes in target gene 
expression in the disease. It is a well-known fact that microRNAs interact with 
mRNAs through MRE binding sites, located on the 3’ UTR of genes, and regulate 
gene expression. Studies have looked into mRNA-microRNA interactions using 
their expression profiles, alternative polyadenylation of 3’UTRs, SNPs along 
MRE sites, etc. However, no study has investigated the use of RNA-Seq data 
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alone to obtain MRE frequencies and gather insights about MREs that show 
evidence of being differentially expressed in tumors until now, and this is being 
addressed in this dissertation. 
 
  Chapter 4 of this dissertation presents a novel bioinformatics approach called 
ReMIx that uses TCGA RNA-Seq data of tumor and normal-adjacent pairs and 
quantifies known MRE sites by screening 3’UTR regions across the whole 
transcriptome. We focused on the TN breast cancer subtype and by using 
definitive statistical measures, identified a set of MREs that showed distinct 
expression in TN tumors, when compared to TN normal-adjacent, ER+, and 
HER2+ subtypes. MRE results from ReMIx also highlighted a) mRNA genes in 
TN tumors that contain the differential MREs, and b) candidate microRNAs that 
have the potential to regulate these genes. Further analysis showed that the 
identified genes belonged to MAPK and PI3K-AKT pathway cascades. These 
genes have direct or indirect interactions with some of the key cancer genes in 
these pathways, such as AKT and Ras oncogenes, which are activated, and 
tumor suppressors such as PTEN and NFKB, which are repressed in TN 
subtype. Finally, we overlaid the TN tumor circRNAs that were obtained from the 
Circ-Seq workflow to these pathways and found that a subset of genes, both 
from the ReMIx analysis as well as gene members of these pathways, contain 
expressed circRNA transcripts.  Here, we have identified a set of mRNA-
microRNA-circRNA candidates that have the potential to interact with each other 
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in a TN tumor-specific manner and regulate some of the vital cancer genes within 
the MAPK and PI3K-AKT pathways.  
 
There are several directions in which work from this dissertation can be pursued 
forward. For example, the mRNA and microRNA candidates identified in chapter 
4 using the ReMIx approach need to be further investigated to elucidate how 
their changes in expression can transmit changes to their neighboring gene 
partners and how this eventually affects the expression of cancer-relevant genes.  
At present, there are no targeted treatment options available for TN breast 
cancer. Identification of novel biomarkers for this disease type is the need of the 
hour, and we hope that the results from this dissertation can help shed light 
towards identifying new targets for TN breast cancer. Studies have shown that 
PIK3CA mutations are found in approximately 20% of breast cancers [122, 135, 
136]. It is hypothesized that PIK3CA may have a role in tumor proliferation in TN 
breast cancer. However, the impact of mutated PIK3CA on the TN subtype has 
not been established [135, 136]. Likewise, mutations in AKT1 are reported in 
about 8% of breast cancers, which lead to higher kinase activity than the wild-
type AKT1 [137], but apparently, this has to be investigated in TN breast cancer. 
MAP-RSeq reports genomic variants such as SNVs and gene fusions as part of 
the workflow output. These reports can be further explored to look into MAPK 
and PI3K-AKT pathways to identify any aberrations in the TN breast cancer 
cases. Further, these findings can be correlated with the ReMIx results to check 
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whether mutations lead to increased or decreased MRE sites in the affected 
genes in TN tumors.  
 
Another prospective approach for ReMIx algorithm in chapter 4 is to analyze the 
ER+ and HER2+ breast cancer subtypes. We have already shown from our Circ-
Seq results for the TCGA ER+ subtype that Luminal A ER+ tumors (which are 
less proliferative) appear to have a higher number of circRNAs compared to the 
more proliferative Luminal B ER+ tumors, indicating that presence of more 
circRNAs tends to control tumor growth. It is not known how this regulatory 
mechanism works, but one could hypothesize that circRNAs in Luminal A tumors 
aid with the sustained activity of tumor suppressor genes by acting as microRNA 
sponges, thereby sequestering microRNAs towards them, which otherwise would 
bind to tumor suppressor genes and induce repression. Our ReMIx methodology 
can be used to identify candidate mRNA-microRNA pairs that show differential 
MRE sites in Luminal A and B ER+ tumors and thereafter, validate whether the 
hypothesis above holds true. Similar analysis can also be performed with 
ER+/HER2+ and ER-/HER2+ in breast cancer and other cancers as well. 
 
The work in this dissertation was focused on using RNA-Seq data alone to 
characterize various features of protein-coding/mRNAs and non-coding 
circRNAs, and also to investigate regulatory elements along 3’UTR regions of 
mRNAs to assess their potential impact on mRNA-microRNA-circRNA 
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interactions in breast cancer. One could extend this work by including data from 
other sequencing applications such as whole-exome (WES) or whole-genome 
(WGS) from DNA-Seq and corroborate the results presented in this dissertation. 
For example, a commonly-used approach is to use WES to verify SNVs identified 
in RNA-Seq. Using SNVs results that are reported by MAPR-Seq for the TCGA 
breast samples, one could integrate SNVs from WES and subset to candidates 
reported in both sequencing types. These SNVs could then be further 
investigated to identify mutation signatures that are specific to the three breast 
cancer subtypes. Another approach is to use WES that includes 3’UTR regions. 
Studies have shown that alternative polyadenylation (APA) can lead to either 
short or long 3’UTRs in TN tumors [138]. Thus, one could inspect whether ReMIx 
gene candidates, with differential MRE sites in TN breast cancer, show 
differences due to dissimilar 3’UTR sizes in tumor and normal-adjacent cases. To 
investigate noncoding RNAs, WGS offers a great validation platform. For 
example, unmapped reads from WGS can be used to confirm the non-coding 
circRNA candidates found by Circ-Seq, by checking for the presence of 3’-5’ 
reads that were identified using RNA-Seq data.  
 
This dissertation has taken a deep dive into non-coding circRNAs and 
understanding their associations with breast cancer subtypes. However, there 
are other non-coding RNAs such as lincRNAs that can also be  brought into the 
picture. As known, lincRNAs are widely present in the human genome, exhibit 
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tissue-specific expression and importantly, have strong regulatory implications on 
target mRNAs [139]. Additionally, lincRNAs can also contain MRE sites along 
their 3’UTR regions and therefore compete with mRNAs and circRNAs for 
microRNA binding [140-142]. Thus, work from this dissertation can be extended 
to include lincRNAs, and potentially other non-coding RNAs like pseudogenes as 
well, to investigate the complex and competitive biological interactions in different 
types of RNAs from tumor and normal cell environments. 
 
In conclusion, the future of bioinformatics research is promising. There is a 
continued demand for bioinformatics advancements, especially towards resolving 
deadly diseases such as cancer and to enable the research community in de-
convoluting the complex biological networks in the transcriptome. We need to 
understand the intricate interactions between various RNA types that lead to the 
ultimate transformation from normal to tumor cells, and bioinformatics research 
can uncover such answers. 
 
 
 
 
  101 
Bibliography 
1. Neafsey DE, Palumbi SR: Genome size evolution in pufferfish: a comparative 
analysis of diodontid and tetraodontid pufferfish genomes. Genome research 
2003, 13:821-830. 
2. Oliver MJ, Petrov D, Ackerly D, Falkowski P, Schofield OM: The mode and 
tempo of genome size evolution in eukaryotes. Genome research 2007, 17:594-
601. 
3. Redi CA, Capanna E: Genome size evolution: sizing mammalian genomes. 
Cytogenetic and genome research 2012, 137:97-112. 
4. Moran LA: Genome Size, Complexity, and the C-Value Paradox. 2007. 
5. Keinath MC, Timoshevskiy VA, Timoshevskaya NY, Tsonis PA, Voss SR, Smith 
JJ: Initial characterization of the large genome of the salamander 
Ambystoma mexicanum using shotgun and laser capture chromosome 
sequencing. Scientific reports 2015, 5:16413. 
6. Clamp M, Fry B, Kamal M, Xie X, Cuff J, Lin MF, Kellis M, Lindblad-Toh K, 
Lander ES: Distinguishing protein-coding and noncoding genes in the human 
genome. Proceedings of the National Academy of Sciences of the United States of 
America 2007, 104:19428-19433. 
7. Alexander RP, Fang G, Rozowsky J, Snyder M, Gerstein MB: Annotating non-
coding regions of the genome. Nature reviews Genetics 2010, 11:559-571. 
8. Frazer KA, Elnitski L, Church DM, Dubchak I, Hardison RC: Cross-species 
sequence comparisons: a review of methods and available resources. Genome 
research 2003, 13:1-12. 
9. An integrated encyclopedia of DNA elements in the human genome. Nature 
2012, 489:57-74. 
10. Djebali S, Davis CA, Merkel A, Dobin A, Lassmann T, Mortazavi A, Tanzer A, 
Lagarde J, Lin W, Schlesinger F, et al: Landscape of transcription in human 
cells. Nature 2012, 489:101-108. 
11. Harrow J, Frankish A, Gonzalez JM, Tapanari E, Diekhans M, Kokocinski F, 
Aken BL, Barrell D, Zadissa A, Searle S, et al: GENCODE: the reference 
human genome annotation for The ENCODE Project. Genome research 2012, 
22:1760-1774. 
12. Ponting CP, Oliver PL, Reik W: Evolution and functions of long noncoding 
RNAs. Cell 2009, 136:629-641. 
13. Malone CD, Hannon GJ: Small RNAs as guardians of the genome. Cell 2009, 
136:656-668. 
14. Carthew RW, Sontheimer EJ: Origins and Mechanisms of miRNAs and 
siRNAs. Cell 2009, 136:642-655. 
15. Balakirev ES, Ayala FJ: Pseudogenes: are they "junk" or functional DNA? 
Annual review of genetics 2003, 37:123-151. 
16. Memczak S, Jens M, Elefsinioti A, Torti F, Krueger J, Rybak A, Maier L, 
Mackowiak SD, Gregersen LH, Munschauer M, et al: Circular RNAs are a 
  102 
large class of animal RNAs with regulatory potency. Nature 2013, 495:333-
338. 
17. Pratt AJ, MacRae IJ: The RNA-induced silencing complex: a versatile gene-
silencing machine. The Journal of biological chemistry 2009, 284:17897-17901. 
18. Pamudurti NR, Bartok O, Jens M, Ashwal-Fluss R, Stottmeister C, Ruhe L, 
Hanan M, Wyler E, Perez-Hernandez D, Ramberger E, et al: Translation of 
CircRNAs. Molecular cell 2017, 66:9-21 e27. 
19. Mullany LE, Herrick JS, Wolff RK, Slattery ML: MicroRNA Seed Region 
Length Impact on Target Messenger RNA Expression and Survival in 
Colorectal Cancer. PloS one 2016, 11:e0154177. 
20. Price C, Chen J: MicroRNAs in Cancer Biology and Therapy: Current Status 
and Perspectives. Genes & diseases 2014, 1:53-63. 
21. Buermans HP, den Dunnen JT: Next generation sequencing technology: 
Advances and applications. Biochimica et biophysica acta 2014, 1842:1932-
1941. 
22. Ozsolak F, Milos PM: RNA sequencing: advances, challenges and 
opportunities. Nature reviews Genetics 2011, 12:87-98. 
23. Creighton CJ, Hernandez-Herrera A, Jacobsen A, Levine DA, Mankoo P, Schultz 
N, Du Y, Zhang Y, Larsson E, Sheridan R, et al: Integrated analyses of 
microRNAs demonstrate their widespread influence on gene expression in 
high-grade serous ovarian carcinoma. PloS one 2012, 7:e34546. 
24. Fackler MJ, Umbricht CB, Williams D, Argani P, Cruz LA, Merino VF, Teo 
WW, Zhang Z, Huang P, Visvananthan K, et al: Genome-wide methylation 
analysis identifies genes specific to breast cancer hormone receptor status 
and risk of recurrence. Cancer research 2011, 71:6195-6207. 
25. Farazi TA, Horlings HM, Ten Hoeve JJ, Mihailovic A, Halfwerk H, Morozov P, 
Brown M, Hafner M, Reyal F, van Kouwenhove M, et al: MicroRNA sequence 
and expression analysis in breast tumors by deep sequencing. Cancer 
research 2011, 71:4443-4453. 
26. Guo L, Zhao Y, Yang S, Zhang H, Chen F: Integrative analysis of miRNA-
mRNA and miRNA-miRNA interactions. BioMed research international 2014, 
2014:907420. 
27. Stricker TP, Brown CD, Bandlamudi C, McNerney M, Kittler R, Montoya V, 
Peterson A, Grossman R, White KP: Robust stratification of breast cancer 
subtypes using differential patterns of transcript isoform expression. PLoS 
genetics 2017, 13:e1006589. 
28. Volinia S, Croce CM: Prognostic microRNA/mRNA signature from the 
integrated analysis of patients with invasive breast cancer. Proceedings of the 
National Academy of Sciences of the United States of America 2013, 110:7413-
7417. 
29. Vu TN, Pramana S, Calza S, Suo C, Lee D, Pawitan Y: Comprehensive 
landscape of subtype-specific coding and non-coding RNA transcripts in 
breast cancer. Oncotarget 2016, 7:68851-68863. 
  103 
30. Zhang Y, Li Y, Wang Q, Zhang X, Wang D, Tang HC, Meng X, Ding X: 
Identification of an lncRNAmiRNAmRNA interaction mechanism in breast 
cancer based on bioinformatic analysis. Molecular medicine reports 2017, 
16:5113-5120. 
31. Kim D, Salzberg SL: TopHat-Fusion: an algorithm for discovery of novel 
fusion transcripts. Genome biology 2011, 12:R72. 
32. Liao Y, Smyth GK, Shi W: featureCounts: an efficient general purpose 
program for assigning sequence reads to genomic features. Bioinformatics 
2014, 30:923-930. 
33. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, 
Garimella K, Altshuler D, Gabriel S, Daly M, DePristo MA: The Genome 
Analysis Toolkit: a MapReduce framework for analyzing next-generation 
DNA sequencing data. Genome research 2010, 20:1297-1303. 
34. Quinlan AR, Hall IM: BEDTools: a flexible suite of utilities for comparing 
genomic features. Bioinformatics 2010, 26:841-842. 
35. Sun K, Zhao Y, Wang H, Sun H: Sebnif: an integrated bioinformatics pipeline 
for the identification of novel large intergenic noncoding RNAs (lincRNAs)--
application in human skeletal muscle cells. PloS one 2014, 9:e84500. 
36. Thorvaldsdottir H, Robinson JT, Mesirov JP: Integrative Genomics Viewer 
(IGV): high-performance genomics data visualization and exploration. 
Briefings in bioinformatics 2013, 14:178-192. 
37. Kalari KR, Nair AA, Bhavsar JD, O'Brien DR, Davila JI, Bockol MA, Nie J, 
Tang X, Baheti S, Doughty JB, et al: MAP-RSeq: Mayo Analysis Pipeline for 
RNA sequencing. BMC bioinformatics 2014, 15:224. 
38. Nair AA, Niu N, Tang X, Thompson KJ, Wang L, Kocher JP, Subramanian S, 
Kalari KR: Circular RNAs and their associations with breast cancer subtypes. 
Oncotarget 2016, 7:80967-80979. 
39. Barrett CL, Schwab RB, Jung H, Crain B, Goff DJ, Jamieson CH, Thistlethwaite 
PA, Harismendy O, Carson DA, Frazer KA: Transcriptome sequencing of 
tumor subpopulations reveals a spectrum of therapeutic options for 
squamous cell lung cancer. PloS one 2013, 8:e58714. 
40. Chen Y, Souaiaia T, Chen T: PerM: efficient mapping of short sequencing 
reads with periodic full sensitive spaced seeds. Bioinformatics 2009, 25:2514-
2521. 
41. Head SR, Mondala T, Gelbart T, Ordoukhanian P, Chappel R, Hernandez G, 
Salomon DR: RNA purification and expression analysis using microarrays 
and RNA deep sequencing. Methods in molecular biology 2013, 1034:385-403. 
42. Robinson MD, McCarthy DJ, Smyth GK: edgeR: a Bioconductor package for 
differential expression analysis of digital gene expression data. Bioinformatics 
2010, 26:139-140. 
43. Wang K, Singh D, Zeng Z, Coleman SJ, Huang Y, Savich GL, He X, 
Mieczkowski P, Grimm SA, Perou CM, et al: MapSplice: accurate mapping of 
RNA-seq reads for splice junction discovery. Nucleic acids research 2010, 
38:e178. 
  104 
44. Goncalves A, Tikhonov A, Brazma A, Kapushesky M: A pipeline for RNA-seq 
data processing and quality assessment. Bioinformatics 2011, 27:867-869. 
45. Habegger L, Sboner A, Gianoulis TA, Rozowsky J, Agarwal A, Snyder M, 
Gerstein M: RSEQtools: a modular framework to analyze RNA-Seq data 
using compact, anonymized data summaries. Bioinformatics 2011, 27:281-283. 
46. Qi J, Zhao F, Buboltz A, Schuster SC: inGAP: an integrated next-generation 
genome analysis pipeline. Bioinformatics 2010, 26:127-129. 
47. Wang Y, Mehta G, Mayani R, Lu J, Souaiaia T, Chen Y, Clark A, Yoon HJ, Wan 
L, Evgrafov OV, et al: RseqFlow: workflows for RNA-Seq data analysis. 
Bioinformatics 2011, 27:2598-2600. 
48. Kalari KR, Nair, A. A: MAP-RSeq website. MC Bioinformatics 2014. 
49. webpage VBd: Virtual Box download webpage. 
50. webpage C: CGHub webpage. 
51. Kent WJ: BLAT--the BLAST-like alignment tool. Genome research 2002, 
12:656-664. 
52. Langmead B, Trapnell C, Pop M, Salzberg SL: Ultrafast and memory-efficient 
alignment of short DNA sequences to the human genome. Genome biology 
2009, 10:R25. 
53. Krzywinski M, Schein J, Birol I, Connors J, Gascoyne R, Horsman D, Jones SJ, 
Marra MA: Circos: an information aesthetic for comparative genomics. 
Genome research 2009, 19:1639-1645. 
54. website F: FASTQC website. 
55. Anders S, Pyl PT, Huber W: HTSeq--a Python framework to work with high-
throughput sequencing data. Bioinformatics 2015, 31:166-169. 
56. webpage PT: Picard Tools webpage. 
57. Wang L, Wang S, Li W: RSeQC: quality control of RNA-seq experiments. 
Bioinformatics 2012, 28:2184-2185. 
58. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis 
G, Durbin R: The Sequence Alignment/Map format and SAMtools. 
Bioinformatics 2009, 25:2078-2079. 
59. Trapnell C, Pachter L, Salzberg SL: TopHat: discovering splice junctions with 
RNA-Seq. Bioinformatics 2009, 25:1105-1111. 
60. Egan JB, Barrett MT, Champion MD, Middha S, Lenkiewicz E, Evers L, Francis 
P, Schmidt J, Shi CX, Van Wier S, et al: Whole genome analyses of a well-
differentiated liposarcoma reveals novel SYT1 and DDR2 rearrangements. 
PloS one 2014, 9:e87113. 
61. Norton N, Sun Z, Asmann YW, Serie DJ, Necela BM, Bhagwate A, Jen J, Eckloff 
BW, Kalari KR, Thompson KJ, et al: Gene expression, single nucleotide 
variant and fusion transcript discovery in archival material from breast 
tumors. PloS one 2013, 8:e81925. 
62. Sakuma T, Davila JI, Malcolm JA, Kocher JP, Tonne JM, Ikeda Y: Murine 
leukemia virus uses NXF1 for nuclear export of spliced and unspliced viral 
transcripts. Journal of virology 2014, 88:4069-4082. 
63. annotation Cia: Cufflink index and annotation. 
  105 
64. Grant GR, Farkas MH, Pizarro AD, Lahens NF, Schug J, Brunk BP, Stoeckert CJ, 
Hogenesch JB, Pierce EA: Comparative analysis of RNA-Seq alignment 
algorithms and the RNA-Seq unified mapper (RUM). Bioinformatics 2011, 
27:2518-2528. 
65. Hardcastle TJ, Kelly KA: baySeq: empirical Bayesian methods for identifying 
differential expression in sequence count data. BMC bioinformatics 2010, 
11:422. 
66. Anders S, Huber W: Differential expression analysis for sequence count data. 
Genome biology 2010, 11:R106. 
67. Smyth GK: Linear models and empirical bayes methods for assessing 
differential expression in microarray experiments. Statistical applications in 
genetics and molecular biology 2004, 3:Article3. 
68. Soneson C, Delorenzi M: A comparison of methods for differential expression 
analysis of RNA-seq data. BMC bioinformatics 2013, 14:91. 
69. Seyednasrollah F, Laiho A, Elo LL: Comparison of software packages for 
detecting differential expression in RNA-seq studies. Briefings in 
bioinformatics 2015, 16:59-70. 
70. Rapaport F, Khanin R, Liang Y, Pirun M, Krek A, Zumbo P, Mason CE, Socci 
ND, Betel D: Comprehensive evaluation of differential gene expression 
analysis methods for RNA-seq data. Genome biology 2013, 14:R95. 
71. Guo JU, Agarwal V, Guo H, Bartel DP: Expanded identification and 
characterization of mammalian circular RNAs. Genome biology 2014, 15:409. 
72. Salzman J, Gawad C, Wang PL, Lacayo N, Brown PO: Circular RNAs are the 
predominant transcript isoform from hundreds of human genes in diverse 
cell types. PloS one 2012, 7:e30733. 
73. Jeck WR, Sorrentino JA, Wang K, Slevin MK, Burd CE, Liu J, Marzluff WF, 
Sharpless NE: Circular RNAs are abundant, conserved, and associated with 
ALU repeats. RNA 2013, 19:141-157. 
74. Suzuki H, Zuo Y, Wang J, Zhang MQ, Malhotra A, Mayeda A: Characterization 
of RNase R-digested cellular RNA source that consists of lariat and circular 
RNAs from pre-mRNA splicing. Nucleic acids research 2006, 34:e63. 
75. Sanger HL, Klotz G, Riesner D, Gross HJ, Kleinschmidt AK: Viroids are single-
stranded covalently closed circular RNA molecules existing as highly base-
paired rod-like structures. Proceedings of the National Academy of Sciences of 
the United States of America 1976, 73:3852-3856. 
76. Diener TO: Viroids: structure and function. Science 1979, 205:859-866. 
77. Capel B, Swain A, Nicolis S, Hacker A, Walter M, Koopman P, Goodfellow P, 
Lovell-Badge R: Circular transcripts of the testis-determining gene Sry in 
adult mouse testis. Cell 1993, 73:1019-1030. 
78. Pasman Z, Been MD, Garcia-Blanco MA: Exon circularization in mammalian 
nuclear extracts. RNA 1996, 2:603-610. 
79. Chao CW, Chan DC, Kuo A, Leder P: The mouse formin (Fmn) gene: 
abundant circular RNA transcripts and gene-targeted deletion analysis. 
Molecular medicine 1998, 4:614-628. 
  106 
80. Ashwal-Fluss R, Meyer M, Pamudurti NR, Ivanov A, Bartok O, Hanan M, 
Evantal N, Memczak S, Rajewsky N, Kadener S: circRNA biogenesis competes 
with pre-mRNA splicing. Molecular cell 2014, 56:55-66. 
81. Wang PL, Bao Y, Yee MC, Barrett SP, Hogan GJ, Olsen MN, Dinneny JR, 
Brown PO, Salzman J: Circular RNA is expressed across the eukaryotic tree 
of life. PloS one 2014, 9:e90859. 
82. Salzman J, Chen RE, Olsen MN, Wang PL, Brown PO: Cell-type specific 
features of circular RNA expression. PLoS genetics 2013, 9:e1003777. 
83. Jeck WR, Sharpless NE: Detecting and characterizing circular RNAs. Nature 
biotechnology 2014, 32:453-461. 
84. Lukiw WJ: Circular RNA (circRNA) in Alzheimer's disease (AD). Frontiers in 
genetics 2013, 4:307. 
85. Valdmanis PN, Kay MA: The expanding repertoire of circular RNAs. 
Molecular therapy : the journal of the American Society of Gene Therapy 2013, 
21:1112-1114. 
86. Li Z, Huang C, Bao C, Chen L, Lin M, Wang X, Zhong G, Yu B, Hu W, Dai L, et 
al: Exon-intron circular RNAs regulate transcription in the nucleus. Nature 
structural & molecular biology 2015, 22:256-264. 
87. Hansen TB, Jensen TI, Clausen BH, Bramsen JB, Finsen B, Damgaard CK, 
Kjems J: Natural RNA circles function as efficient microRNA sponges. Nature 
2013, 495:384-388. 
88. Bahn JH, Zhang Q, Li F, Chan TM, Lin X, Kim Y, Wong DT, Xiao X: The 
landscape of microRNA, Piwi-interacting RNA, and circular RNA in human 
saliva. Clinical chemistry 2015, 61:221-230. 
89. Li Y, Zheng Q, Bao C, Li S, Guo W, Zhao J, Chen D, Gu J, He X, Huang S: 
Circular RNA is enriched and stable in exosomes: a promising biomarker for 
cancer diagnosis. Cell research 2015, 25:981-984. 
90. Yang JH, Li JH, Shao P, Zhou H, Chen YQ, Qu LH: starBase: a database for 
exploring microRNA-mRNA interaction maps from Argonaute CLIP-Seq 
and Degradome-Seq data. Nucleic acids research 2011, 39:D202-209. 
91. Bachmayr-Heyda A, Reiner AT, Auer K, Sukhbaatar N, Aust S, Bachleitner-
Hofmann T, Mesteri I, Grunt TW, Zeillinger R, Pils D: Correlation of circular 
RNA abundance with proliferation--exemplified with colorectal and ovarian 
cancer, idiopathic lung fibrosis, and normal human tissues. Scientific reports 
2015, 5:8057. 
92. Ghosal S, Das S, Sen R, Basak P, Chakrabarti J: Circ2Traits: a comprehensive 
database for circular RNA potentially associated with disease and traits. 
Frontiers in genetics 2013, 4:283. 
93. Nielsen TO, Parker JS, Leung S, Voduc D, Ebbert M, Vickery T, Davies SR, 
Snider J, Stijleman IJ, Reed J, et al: A comparison of PAM50 intrinsic 
subtyping with immunohistochemistry and clinical prognostic factors in 
tamoxifen-treated estrogen receptor-positive breast cancer. Clinical cancer 
research : an official journal of the American Association for Cancer Research 
2010, 16:5222-5232. 
  107 
94. Sun Z, Asmann YW, Kalari KR, Bot B, Eckel-Passow JE, Baker TR, Carr JM, 
Khrebtukova I, Luo S, Zhang L, et al: Integrated analysis of gene expression, 
CpG island methylation, and gene copy number in breast cancer cells by 
deep sequencing. PloS one 2011, 6:e17490. 
95. Dai X, Li Y, Bai Z, Tang XQ: Molecular portraits revealing the heterogeneity 
of breast tumor subtypes defined using immunohistochemistry markers. 
Scientific reports 2015, 5:14499. 
96. Pouladi N, Cowper-Sallari R, Moore JH: Combining functional genomics 
strategies identifies modular heterogeneity of breast cancer intrinsic 
subtypes. BioData mining 2014, 7:27. 
97. Martin M, Prat A, Rodriguez-Lescure A, Caballero R, Ebbert MT, Munarriz B, 
Ruiz-Borrego M, Bastien RR, Crespo C, Davis C, et al: PAM50 proliferation 
score as a predictor of weekly paclitaxel benefit in breast cancer. Breast 
cancer research and treatment 2013, 138:457-466. 
98. Zhang B, Kirov S, Snoddy J: WebGestalt: an integrated system for exploring 
gene sets in various biological contexts. Nucleic acids research 2005, 33:W741-
748. 
99. Aherne ST, Madden SF, Hughes DJ, Pardini B, Naccarati A, Levy M, Vodicka P, 
Neary P, Dowling P, Clynes M: Circulating miRNAs miR-34a and miR-150 
associated with colorectal cancer progression. BMC cancer 2015, 15:329. 
100. Hoffman Y, Bublik DR, Pilpel Y, Oren M: miR-661 downregulates both Mdm2 
and Mdm4 to activate p53. Cell death and differentiation 2014, 21:302-309. 
101. Illumina: Illumina TrueSeq RNA preperation. 
102. Prueitt RL, Yi M, Hudson RS, Wallace TA, Howe TM, Yfantis HG, Lee DH, 
Stephens RM, Liu CG, Calin GA, et al: Expression of microRNAs and protein-
coding genes associated with perineural invasion in prostate cancer. The 
Prostate 2008, 68:1152-1164. 
103. Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N, Yuen 
ST, Chan TL, Kwong DL, Au GK, et al: MicroRNA expression profiles 
associated with prognosis and therapeutic outcome in colon adenocarcinoma. 
JAMA 2008, 299:425-436. 
104. Lee S, Jiang X: Modeling miRNA-mRNA interactions that cause phenotypic 
abnormality in breast cancer patients. PloS one 2017, 12:e0182666. 
105. Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J, Bartel DP, 
Linsley PS, Johnson JM: Microarray analysis shows that some microRNAs 
downregulate large numbers of target mRNAs. Nature 2005, 433:769-773. 
106. Krek A, Grun D, Poy MN, Wolf R, Rosenberg L, Epstein EJ, MacMenamin P, da 
Piedade I, Gunsalus KC, Stoffel M, Rajewsky N: Combinatorial microRNA 
target predictions. Nature genetics 2005, 37:495-500. 
107. Jacobsen A, Silber J, Harinath G, Huse JT, Schultz N, Sander C: Analysis of 
microRNA-target interactions across diverse cancer types. Nature structural 
& molecular biology 2013, 20:1325-1332. 
  108 
108. Han S, Kim D, Shivakumar M, Lee YJ, Garg T, Miller JE, Kim JH, Lee Y: The 
effects of alternative splicing on miRNA binding sites in bladder cancer. PloS 
one 2018, 13:e0190708. 
109. Pelletier C, Weidhaas JB: MicroRNA binding site polymorphisms as 
biomarkers of cancer risk. Expert review of molecular diagnostics 2010, 
10:817-829. 
110. Comprehensive molecular portraits of human breast tumours. Nature 2012, 
490:61-70. 
111. Ciriello G, Gatza ML, Beck AH, Wilkerson MD, Rhie SK, Pastore A, Zhang H, 
McLellan M, Yau C, Kandoth C, et al: Comprehensive Molecular Portraits of 
Invasive Lobular Breast Cancer. Cell 2015, 163:506-519. 
112. Grant CE, Bailey TL, Noble WS: FIMO: scanning for occurrences of a given 
motif. Bioinformatics 2011, 27:1017-1018. 
113. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, 
Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP: Gene set 
enrichment analysis: a knowledge-based approach for interpreting genome-
wide expression profiles. Proceedings of the National Academy of Sciences of 
the United States of America 2005, 102:15545-15550. 
114. Agarwal V, Bell GW, Nam JW, Bartel DP: Predicting effective microRNA 
target sites in mammalian mRNAs. eLife 2015, 4. 
115. Sun Z, Evans J, Bhagwate A, Middha S, Bockol M, Yan H, Kocher JP: CAP-
miRSeq: a comprehensive analysis pipeline for microRNA sequencing data. 
BMC genomics 2014, 15:423. 
116. Le Pera L, Mazzapioda M, Tramontano A: 3USS: a web server for detecting 
alternative 3'UTRs from RNA-seq experiments. Bioinformatics 2015, 31:1845-
1847. 
117. John B, Enright AJ, Aravin A, Tuschl T, Sander C, Marks DS: Human 
MicroRNA targets. PLoS biology 2004, 2:e363. 
118. Skeeles LE, Fleming JL, Mahler KL, Toland AE: The impact of 3'UTR variants 
on differential expression of candidate cancer susceptibility genes. PloS one 
2013, 8:e58609. 
119. Saini K, J Piccart-Gebhart M: Dual targeting of the PI3K and MAPK pathways in 
breast cancer. 2010. 
120. Balko JM, Miller TW, Morrison MM, Hutchinson K, Young C, Rinehart C, 
Sanchez V, Jee D, Polyak K, Prat A, et al: The receptor tyrosine kinase ErbB3 
maintains the balance between luminal and basal breast epithelium. 
Proceedings of the National Academy of Sciences of the United States of America 
2012, 109:221-226. 
121. Hoeflich KP, O'Brien C, Boyd Z, Cavet G, Guerrero S, Jung K, Januario T, 
Savage H, Punnoose E, Truong T, et al: In vivo antitumor activity of MEK and 
phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. 
Clinical cancer research : an official journal of the American Association for 
Cancer Research 2009, 15:4649-4664. 
  109 
122. Hashimoto K, Tsuda H, Koizumi F, Shimizu C, Yonemori K, Ando M, Kodaira 
M, Yunokawa M, Fujiwara Y, Tamura K: Activated PI3K/AKT and MAPK 
pathways are potential good prognostic markers in node-positive, triple-
negative breast cancer. Annals of oncology : official journal of the European 
Society for Medical Oncology 2014, 25:1973-1979. 
123. Loi S, Dushyanthen S, Beavis PA, Salgado R, Denkert C, Savas P, Combs S, 
Rimm DL, Giltnane JM, Estrada MV, et al: RAS/MAPK Activation Is 
Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-
Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-
1/PD-L1 Immune Checkpoint Inhibitors. Clinical cancer research : an official 
journal of the American Association for Cancer Research 2016, 22:1499-1509. 
124. Qi X, Yin N, Ma S, Lepp A, Tang J, Jing W, Johnson B, Dwinell MB, Chitambar 
CR, Chen G: p38gamma MAPK Is a Therapeutic Target for Triple-Negative 
Breast Cancer by Stimulation of Cancer Stem-Like Cell Expansion. Stem 
cells 2015, 33:2738-2747. 
125. Gholami S, Chen CH, Gao S, Lou E, Fujisawa S, Carson J, Nnoli JE, Chou TC, 
Bromberg J, Fong Y: Role of MAPK in oncolytic herpes viral therapy in 
triple-negative breast cancer. Cancer gene therapy 2014, 21:283-289. 
126. Giltnane JM, Balko JM: Rationale for targeting the Ras/MAPK pathway in 
triple-negative breast cancer. Discovery medicine 2014, 17:275-283. 
127. Eralp Y, Derin D, Ozluk Y, Yavuz E, Guney N, Saip P, Muslumanoglu M, Igci A, 
Kucucuk S, Dincer M, et al: MAPK overexpression is associated with 
anthracycline resistance and increased risk for recurrence in patients with 
triple-negative breast cancer. Annals of oncology : official journal of the 
European Society for Medical Oncology 2008, 19:669-674. 
128. Massihnia D, Galvano A, Fanale D, Perez A, Castiglia M, Incorvaia L, Listi A, 
Rizzo S, Cicero G, Bazan V, et al: Triple negative breast cancer: shedding 
light onto the role of pi3k/akt/mtor pathway. Oncotarget 2016, 7:60712-60722. 
129. de Lint K, Poell JB, Soueidan H, Jastrzebski K, Vidal Rodriguez J, Lieftink C, 
Wessels LF, Beijersbergen RL: Sensitizing Triple-Negative Breast Cancer to 
PI3K Inhibition by Cotargeting IGF1R. Molecular cancer therapeutics 2016, 
15:1545-1556. 
130. Kriegsmann M, Endris V, Wolf T, Pfarr N, Stenzinger A, Loibl S, Denkert C, 
Schneeweiss A, Budczies J, Sinn P, Weichert W: Mutational profiles in triple-
negative breast cancer defined by ultradeep multigene sequencing show high 
rates of PI3K pathway alterations and clinically relevant entity subgroup 
specific differences. Oncotarget 2014, 5:9952-9965. 
131. Lehmann BD, Bauer JA, Schafer JM, Pendleton CS, Tang L, Johnson KC, Chen 
X, Balko JM, Gomez H, Arteaga CL, et al: PIK3CA mutations in androgen 
receptor-positive triple negative breast cancer confer sensitivity to the 
combination of PI3K and androgen receptor inhibitors. Breast cancer 
research : BCR 2014, 16:406. 
132. De P, Sun Y, Carlson JH, Friedman LS, Leyland-Jones BR, Dey N: Doubling 
down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of 
  110 
PARP inhibitor in triple negative breast cancer model beyond BRCA-ness. 
Neoplasia 2014, 16:43-72. 
133. Yi YW, Hong W, Kang HJ, Kim HJ, Zhao W, Wang A, Seong YS, Bae I: 
Inhibition of the PI3K/AKT pathway potentiates cytotoxicity of EGFR 
kinase inhibitors in triple-negative breast cancer cells. Journal of cellular and 
molecular medicine 2013, 17:648-656. 
134. Ibrahim YH, Garcia-Garcia C, Serra V, He L, Torres-Lockhart K, Prat A, Anton 
P, Cozar P, Guzman M, Grueso J, et al: PI3K inhibition impairs BRCA1/2 
expression and sensitizes BRCA-proficient triple-negative breast cancer to 
PARP inhibition. Cancer discovery 2012, 2:1036-1047. 
135. Kalinsky K, Jacks LM, Heguy A, Patil S, Drobnjak M, Bhanot UK, Hedvat CV, 
Traina TA, Solit D, Gerald W, Moynahan ME: PIK3CA mutation associates 
with improved outcome in breast cancer. Clinical cancer research : an official 
journal of the American Association for Cancer Research 2009, 15:5049-5059. 
136. Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, 
Linn SC, Gonzalez-Angulo AM, Stemke-Hale K, Hauptmann M, et al: A 
functional genetic approach identifies the PI3K pathway as a major 
determinant of trastuzumab resistance in breast cancer. Cancer cell 2007, 
12:395-402. 
137. Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL, Robbins CM, Hostetter 
G, Boguslawski S, Moses TY, Savage S, et al: A transforming mutation in the 
pleckstrin homology domain of AKT1 in cancer. Nature 2007, 448:439-444. 
138. Miles WO, Lembo A, Volorio A, Brachtel E, Tian B, Sgroi D, Provero P, Dyson 
N: Alternative Polyadenylation in Triple-Negative Breast Tumors Allows 
NRAS and c-JUN to Bypass PUMILIO Posttranscriptional Regulation. 
Cancer research 2016, 76:7231-7241. 
139. Wang Q, Gao S, Li H, Lv M, Lu C: Long noncoding RNAs (lncRNAs) in triple 
negative breast cancer. Journal of cellular physiology 2017, 232:3226-3233. 
140. Eades G, Wolfson B, Zhang Y, Li Q, Yao Y, Zhou Q: lincRNA-RoR and miR-
145 regulate invasion in triple-negative breast cancer via targeting ARF6. 
Molecular cancer research : MCR 2015, 13:330-338. 
141. Xia T, Liao Q, Jiang X, Shao Y, Xiao B, Xi Y, Guo J: Long noncoding RNA 
associated-competing endogenous RNAs in gastric cancer. Scientific reports 
2014, 4:6088. 
142. Zhao Y, Wang H, Wu C, Yan M, Wu H, Wang J, Yang X, Shao Q: Construction 
and investigation of lncRNA-associated ceRNA regulatory network in 
papillary thyroid cancer. Oncology reports 2018, 39:1197-1206. 
 
 
 
 
  111 
 
Appendix  
 
6.1 Permissions  
 
 
This section contains Creative Commons license agreement and journal 
permissions obtained from BMC Bioinformatics and Oncotarget to reproduce 
published articles that are part of this dissertation. Snapshots of the published 
articles are also provided. 
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Figure 26: Permission from BMC Bioinformatics to reproduce MAP-RSeq 
publication  
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Figure 27: Snapshot of publication for MAP-RSeq workflow 
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Figure 28: Permission from Oncotarget to reproduce circular RNA publication 
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Figure 29: Creative Commons license agreement used by Oncotarget 
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Figure 30: Snapshot of publication for Circ-Seq workflow and circular RNA 
associations found in breast cancer 
